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I. Risk of Orthostatic Intolerance During Re-Exposure to Gravity  
 Post-flight orthostatic intolerance, the inability to maintain blood pressure while in an 
upright position, is an established, spaceflight-related medical problem. Countermeasures 
have been identified and implemented with some success (exercise, fluid loading, 
compression garments). Completion of these efforts is essential for determining what 
preventive measures should be used to combat orthostatic intolerance during future 
mission profiles.  
 
II. Executive Summary 
 Post-spaceflight orthostatic intolerance remains a significant concern to NASA.  In 
Space Shuttle missions, astronauts wore anti-gravity suits and liquid cooling garments to 
protect against orthostatic intolerance during re-entry and landing, but in-flight exercise 
and the end-of-mission fluid loading failed to protect ~30% of Shuttle astronauts when 
these garments were not worn.  The severity of the problem appears to be increased after 
long-duration space flight.  Five of six US astronauts could not complete a 10-minutes 
upright-posture tilt testing (1) on landing day following 4-5 month stays aboard the Mir 
space station (1).  The majority of these astronauts had experienced no problems of 
orthostatic intolerance following their shorter Shuttle flights.  More recently, four of six 
US astronauts could not complete a tilt test on landing day following ~6 month stays on 
the International Space Station (2).  Similar observations were made in the Soviet and 
Russian space programs, such that some cosmonauts wear the Russian compression 
garments (Kentavr) up to 4 days after landing (3).   Future exploration missions, such as 
those to Mars or Near Earth Objects, will be long duration, and astronauts will be landing 
on planetary bodies with no ground-support teams.  The occurrence of severe orthostatic 
hypotension could threaten the astronauts’ health and safety and success of the mission.   
 
 
III. Introduction  
 Human evolution has been driven by the environment in which we exist.  One major 
component of the environment that has influenced the development of the cardiovascular 
system is gravity.  For our purposes, the human body is essentially a column of water and 
the hydrostatic forces that act on this column, due to our upright posture and bipedal 
locomotion, have led to a very complex system of controls to maintain blood flow to the 
brain.  Removing humans from the effects of gravity, as well as returning them to Earth-
gravity from microgravity, presents the body with significant challenges to this control 
system. 
 It is well documented that the cardiovascular system is affected by spaceflight.  
However, the mechanisms behind the changes in cardiovascular function due to 
spaceflight are still not completely understood.  One of the most important changes 
negatively impacting flight operations and crew safety is postflight orthostatic 
intolerance.  Astronauts who have orthostatic intolerance are unable to maintain arterial 
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pressure and cerebral perfusion during upright posture, and may experience presyncope 
or, ultimately, syncope.  This may impair their ability to egress the vehicle after landing.  
This problem affects about 20-30% of crewmembers that fly short duration missions (4-
18 days) (4–6) and 83% of astronauts that fly long duration missions (1) when subjected 
to a stand or tilt test.  Anecdotal reports, one documented by live media coverage, 
confirm that some astronauts have difficulty with everyday activities such as press 
conferences, showering, using the restroom or ambulating after a meal.  The number 
affected in this way is much more difficult to accurately document as they are not 
reported in the literature. 
   
 
Figure 1. Diagram of the effects of exposure to microgravity on orthostatic intolerance.  Taken from 
Pavy-Le Traon et al. (7) 
 
 The etiology of orthostatic intolerance is complicated and multifactorial, as shown in 
Figure 1.  While the decrease in plasma volume, secondary to the headward fluid shift 
that occurs in space, is an important initiating event in the etiology of orthostatic 
intolerance, it is the downstream effects and the physiological responses (or lack thereof) 
that may lead to orthostatic intolerance.  This is highlighted by the fact that while all 
crewmembers that have been tested are hypovolemic on landing day, only a fraction of 
them develop orthostatic intolerance during stand/tilt testing.   
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 One physiological mechanism that has been shown to contribute to post-spaceflight 
orthostatic intolerance is dysfunction of the sympathetic nervous system (8), with or 
without failure of the renin-angiotensin-aldosterone system (9).  These two control 
systems are activated with postural changes to the upright position.  As central blood 
volume pools in the lower extremities, aortic-carotid baroreceptors are stimulated by low 
blood pressure (BP), and cardiopulmonary baroreceptors are stimulated by low blood 
volume.  The baroreflex response via the aortic-carotid pathway is to stimulate the 
sympathetic nervous system to release norepinephrine, which causes systemic 
vasoconstriction and increases cardiac contractility, thereby maintaining blood pressure.  
The baroreflex response via the cardiopulmonary pathway is to stimulate the renin-
angiotensin-aldosterone system which causes sodium and water reabsorption to maintain 
central blood volume and blood pressure.  If the sympathetic nervous system and/or 
renin-angiotensin-aldosterone system are inhibited, orthostatic intolerance may occur.   
 Another possible mechanism for post-spaceflight orthostatic hypotension is cardiac 
atrophy and the resulting decrease in stroke volume (SV), as has been shown in multiple 
bed rest studies and a flight study (10,11).  Stroke volume is easily altered by mechanical 
and hydrostatic effects and serves as the primary stimulus to baroreflex regulation of 
arterial pressure during an orthostatic stress as part of the “triple product” of blood 
pressure control:  BP = HR (heart rate) × SV × TPR (total peripheral resistance) (12).  
Orthostatic hypotension will ensue if the fall in stroke volume is of sufficient magnitude 
to overwhelm normal compensatory mechanisms or if the reflex increase in HR and/or 
TPR is impaired by disease states or by a specific adaptation of the autonomic nervous 
system (13). 
 After adaptation to real or simulated microgravity, virtually all individuals studied 
have an excessive fall in stroke volume in the upright position (4,14). Although there are 
conflicting data regarding changes in baroreflex regulation of heart rate and vascular 
resistance that may limit the compensatory response to orthostasis (15–23), it may be this 
excessive fall in stroke volume that is the critical factor of microgravity induced 
orthostatic hypotension. 
While orthostatic intolerance is perhaps the most comprehensively studied 
cardiovascular effect of spaceflight, the mechanisms are not well understood.  Enough is 
known to allow for the implementation of some countermeasures, yet none of these 
countermeasures alone has been completely successful at eliminating spaceflight-induced 
orthostatic intolerance following spaceflight. The combination of multiple 
countermeasures (fluid loading, re-entry compression garments and post-landing 
compression garments) and immediate access to medical care has been successful at 
controlling this risk for short duration flights.  Once the post-landing garments have been 
validated following long duration flights, it is likely that this risk will also be controlled. 
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IV. Evidence 
 
A. Orthostatic Intolerance after Space Flight 
  
The Mercury (1961-1963) and Gemini (1965-1966) missions opened the door for 
exploration of the physiological effects of spaceflight in humans.  Post-spaceflight 
orthostatic intolerance became evident when the pilot of Mercury-Atlas 9 became 
hypotensive during an upright 70º tilt test after only 34 hours of flight. Thereafter, tilt 
testing was performed before and after spaceflight throughout the end of the Gemini 
Program. The results of the postflight tests consistently yielded increased heart rate, 
decreased pulse pressure and increased fluid pooling in the lower extremities for up to 50 
hours after splashdown, confirming a decrease in orthostatic tolerance after spaceflight in 
missions of 3-14 days (24).  
Based on the cardiovascular changes observed during the Mercury and Gemini 
missions, testing was extended during the Apollo Program (1968-1972) to achieve a more 
comprehensive understanding of the physiological effects of spaceflight. However, 
spacecraft constraints, astronaut schedules and primary mission objectives did not allow 
for extensive testing, and only those tests considered most important were performed. 
Because of the easier instrumentation, control of different levels of stresses and potential 
for future inflight use, lower body negative pressure (LBNP) was implemented (protocol 
in Figure 2) as a test for orthostatic intolerance (24). However, postflight quarantine 
protocols exercised on Apollo 10-14 prevented the use of LBNP; and thus stand tests, 
which had been validated in Apollo 9, were performed after Apollo 10 and 11, whereas 
no tests of orthostatic intolerance were performed on Apollo 12-14 (24).  
   9 
 
Figure 2. LBNP protocol as used during the Apollo program for testing orthostatic tolerance. 
(24) 
 
The change in atmosphere composition and increased mobility in the spacecraft in the Apollo 
missions were predicted to reduce post-spaceflight orthostatic intolerance compared to the 
Mercury program; however, orthostatic intolerance remained prevalent. The Apollo 16 and 17 
missions introduced countermeasures for orthostatic intolerance in the form of anti-hypotensive 
garments (24).  Though the countermeasure appeared to provide moderate protection against 
orthostatic hypotension, testing in Apollo 16 was plagued with problems. The countermeasure for 
this flight was Jobst compression stockings with a pressure of 40-45 mmHg at the ankle and 
linearly decreasing pressure to the waist at 10 mmHg. The tight space inside the spacecraft 
prevented the crewmembers from donning the stockings inflight, such that the stockings were 
only worn for a stand test after the LBNP orthostatic tolerance test. Additionally, the stockings 
could not be fitted accurately for postflight testing due to the unquantifiable decrease in leg 
circumference. Finally, postflight testing was performed with ambient temperatures 10ºC higher 
than preflight testing, augmenting the orthostatic stresses.  Conversely, the countermeasure and 
testing conditions in Apollo 17 successfully prevented heart rate changes during LBNP. In this 
mission, the orthostatic test was performed in the air-conditioned Skylab Mobile Laboratory, and 
the anti-hypotension suit was an inflatable suit which applied lower body positive pressure from 
the ankles to the waist. The crewmember donned the garment before reentry, inflated it after 
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splashdown while still in the spacecraft and did not deflate the suit until ten minutes had elapsed 
in the passive stand test (Figure 3). Though the crewmember did not exhibit the typical change in 
heart rate during LBNP, it should be noted that he also did not follow the trend in cardiothoracic 
ratio change and postflight limb volume changes (24). 
 
Figure 3. Anti-hypotensive suit protocol followed by 1 crewmember on Apollo 17(24). 
 
Of the twenty-one Apollo astronauts (twenty-four total flights) that performed pre- and post-
spaceflight orthostatic tolerance tests, thirteen exhibited an increased heart rate when at rest 
postflight. This heart rate returned to preflight values by the third examination, two to three days 
after splashdown. During immediate postflight orthostatic evaluations, astronauts exhibited an 
increase in heart rate and a decrease in stroke volume and systolic and pulse pressures that were 
greater than those responses before flight.  These increases in heart rate were not correlated with 
mission durations of 8-14 days.  Additionally, body weight, calf circumference and cardiothoracic 
ratio were all decreased immediately postflight. These measurements had not returned to their 
preflight values by the third postflight examination, suggesting the changes were not entirely due 
to fluid loss (24). The findings of the Apollo Program aided the understanding of cardiovascular 
changes in spaceflight in preparation for longer duration spaceflight in the Skylab missions.  
Skylab missions (1973-1974) began the era of long duration spaceflight, where each mission 
set the record for amount of time spent in space (28, 59 and 84 days) by astronauts. The larger 
spacecraft and longer duration of the missions allowed the Skylab program to assess the effects of 
spaceflight on more physiological parameters. However, the high cost of extensive hardware 
prohibited implementation of many inflight measurements that we need today (25).  The use of 
lower body negative pressure was extended from the Apollo Program, where LBNP was used as 
an orthostatic tolerance test pre- and post-spaceflight, to include in-flight testing as well. Inflight 
LBNP revealed the existence of orthostatic intolerance after 4 to 6 days of flight(26). Crewmen 
experienced a greater stress during inflight LBNP than preflight LBNP(25), which is illustrated 
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by their greater increases in heart rate and leg volume and greater decreases in systolic blood 
pressure (26). Inflight LBNP also served as an indicator of the degree of postflight orthostatic 
intolerance, information that aided crew health care after long duration missions. 
Research from Gemini and Apollo suggested a decrease in cardiac function accompanying 
spaceflight, raising concerns about potential detrimental effects of long duration spaceflight on 
the cardiovascular system. Postflight clinical data suggested there might be an impediment to 
venous return as well as a myocardial effect causing decreased cardiovascular function (25). Two 
of the three astronauts in Skylab 4 had decreased stroke volume and cardiac output upon their 
return to Earth, yet the rapid recovery of cardiac volume and mass to preflight values led to the 
conclusion that 84 days in space is not a long-enough time to produce irreversible cardiac 
dysfunction (27). The cardiovascular studies that were performed on Skylab provided information 
about hemodynamic changes that will be valuable for future short and long duration spaceflights, 
including space station habitation. 
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Figure 4. Changes in heart rate and blood pressure during spaceflight (28). 
 
The Extended Duration Orbiter Medical Project (EDOMP; 1989-1995) aimed to define the 
effects of short duration spaceflight in a more-controlled environment aboard the Space Shuttle 
Orbiter with a larger subject pool, understand the changes in cardiovascular physiology, and 
develop appropriate countermeasures to prevent detrimental effects of spaceflight (28). 
Descriptive changes on the cardiovascular system were determined in several studies, in which 
24-hour Holter monitoring, blood pressure recordings and two-dimensional echocardiography 
were determined in flight, and heart rate and blood pressures were determined during launch and 
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reentry.  Inflight heart rate and systolic and diastolic blood pressure were decreased when 
compared to the preflight values, as can be seen in Figure 4. Upon reentry, these values increased 
past their preflight baseline, reaching maximal values at peak gravity (28). Such reentry 
measurements are no longer performed. During crewmember standing after touchdown, both 
systolic and diastolic pressures significantly decreased from the seated value, and the decrease in 
diastolic pressure was greater in the crewmembers who did not inflate their g-suits. Systolic 
pressure and heart rate returned to preflight values within an hour of landing, whereas all other 
spaceflight-induced cardiovascular changes were reversed within a week after landing.   
Four mechanistic studies were performed to explore the etiology of post-spaceflight 
orthostatic hypotension, concentrating on changes in autonomic control (28). The first three 
studies concluded post-spaceflight cardiovascular responses were characterized by decreased 
orthostatic tolerance, increased low-frequency R-R spectral power, decreased carotid 
baroreceptor response, and altered blood pressure and heart rate responses to Valsalva maneuvers. 
Catecholamine analyses revealed norepinephrine and epinephrine levels were increased when he 
astronauts were both resting and standing postflight (Figure 5). Three days after landing, the 
astronauts’ norepinephrine levels when they were standing remained increased, while their 
epinephrine levels had returned to preflight values. The fourth mechanistic study delved into the 
differences between postflight presyncopal and non-presyncopal crewmembers, and found those 
in the non-presyncopal group had significantly greater norepinephrine response upon standing, 
leading to greater peripheral vascular resistance. Analysis of preflight data yielded normal 
cardiovascular measures in both groups, yet the presyncopal group was characterized by 
significantly lower diastolic blood pressure and lower systolic blood pressure and peripheral 
vascular resistance when they were supine. However, it should be noted that plasma volume 
losses were not significantly different between the presyncopal and non-presyncopal groups (28). 
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Figure 5. Supine (n=23-24) and standing (n=15-16) catecholamine analysis pre- and post-
spaceflight ((28).  
 
The last goal of the EDOMP, evaluating countermeasures to increase postflight plasma 
volume, consisted of four studies implementing different LBNP protocols, salt and fluid loading, 
and fludrocortisone (28). The first protocol applied lower body negative pressure in a step-wise 
fashion ranging from 0 to -60 mmHg in 5-minute intervals (ramp).  The treatment (soak) 
consisted of a ramp to -50 mmHg, followed by a decompression at -30 mmHg for approximately 
3.5 hours with a fluid and salt load during the first hour. The pre- and post-soak ramps were 
compared, and results showed the heart rate response post-soak was significantly less than that 
pre-soak, suggesting the soak treatment was effective for the first 24 hours. The second LBNP 
protocol required crewmembers to perform a soak within the 24 hours before landing. Upon 
landing, diastolic pressures and heart rate when the astronauts were seated and standing were 
lower in the LBNP group than in crewmembers who did not perform the soak. However, testing 
conducted one to three hours after landing showed no significant differences in heart rate or blood 
pressures during a stand test as well as no significant differences in plasma volume losses. The 
third countermeasure study (which was instituted well before EDOMP), a mandatory fluid and 
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salt load before reentry (6), did not allow for any conclusions due to a lack of control of fluid 
ingestion inflight and postflight before testing. The last countermeasure, fludrocortisone, proved 
unsuccessful since it was not well-tolerated by the crewmembers and did not result in any 
differences in plasma volume or orthostatic tolerance (28). The implemented countermeasures in 
the EDOMP were not successful in preventing post-spaceflight orthostatic intolerance. However, 
the  knowledge gained about spaceflight-induced cardiovascular changes and differences between 
orthostatic tolerance groups has provided a base for development of future pharmacological and 
mechanical countermeasures.  
Since EDOMP, investigators continue to report orthostatic intolerance following spaceflight.  
   
Figure 6.  Hemodynamic responses to standing (5 finishers, 7-9 non finishers) before and 
after spaceflight (14).  
 
Buckey et al (14) showed these effects following three Spacelab missions (Figure 6).  They 
found an increase in heart rate, decrease in systolic pressure and a decrease in stroke volume 
during a post-spaceflight five-minute stand test; all of these are hallmarks of orthostatic 
intolerance.  Other studies, utilizing a ten-minute stand/tilt test have shown similar results (Figure 
7)  as well as a decrease in standing time following short duration spaceflight (1,4–6,29).  These 
studies report orthostatic hypotension that results in presyncope (light headedness, nausea, tunnel 
vision, or a systolic pressure below 70 mmHg) in 20-30% of returning crewmembers.     
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Figure 7.  Summary survival analysis of  Shuttle, MIR and ISS crewmembers.   
 
The data for long duration crewmembers is more limited, but suggests a more severe 
spaceflight effect.  The incidence of post-spaceflight orthostatic hypotension among US 
astronauts increased to greater than 80% on landing day following long duration (~ 6 months) 
spaceflights; 5 of 6 astronauts could not complete a 10-min tilt test after Mir Space Station 
missions (1).  The survival analysis in Figure 7 shows this difference where the 50% survival is 
much lower as is the total failure rate at 10 minutes (compared to short duration spaceflight).  It is 
interesting to note that this figure also shows that even long duration crew have recovered 
sufficiently to pass a 10-minute tilt test following only one day of recovery.   
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Figure 8.  Effects of spaceflight on a single crewmember.  Left panels show the blood pressure 
responses to an 80-degree head-up tilt.  Right panels show the norepinephrine released during the 
tilt. This crewmember completed the tilt after short duration spaceflight with normal norepinephrine 
response, while he failed the tilt test after ~2 minutes following long duration spaceflight and did not 
increase norepinephrine release upon exposure to tilt. 
 
Figure 8 shows the tilt responses of a single astronaut to both a short duration flight (top) and 
a long duration Mir flight (bottom).  These data show a normal tilt response following a shuttle 
flight with no indications of orthostatic intolerance and a normal norepinephrine increase to tilt.  
The bottom panel, however, shows that following long duration spaceflight the crewmember 
could not complete more than two minutes of tilt before hypotension caused the test to be 
terminated.  This crewmember also failed to mount any adrenergic response to tilt following this 
long duration spaceflight. 
 An important point that must be made is that these survival analyses under report the true 
rate of orthostatic intolerance on landing day, because crewmembers who are very ill on landing 
day are either not tested (and are thus not included in these calculation) or testing is delayed until 
the crewmember is sufficiently well to participate in testing (see detailed discussion below).  
Thus the true figures for presyncope following short duration spaceflight and long duration 
spaceflight are, in reality, higher than the reported incidences of 20-30% and 83%, respectively. 
More recently, a review of tilt tests results from US astronauts after International Space 
Station and Space Shuttle missions also revealed a higher incidence of presyncope after long-
duration missions compared to short-duration flights (2).  On landing day, 4 of 6 (66%) ISS 
astronauts were unable to complete a 10-min 80° head-up tilt test compared to 13 of 66 (20%) 
   18 
Shuttle astronauts.  However, the rates of presyncope quickly decline after just one day after 
return from space; 8 of an additional 9 ISS astronauts completed the tilt test on R+1.  On R+3, 13 
of 15 (87%) of the ISS and 19 of 19 (100%) of the Shuttle astronauts completed the 10-min test.  
However, statistical modeling of cardiovascular parameters associated with orthostatic 
hypotension, specifically stroke volume and diastolic blood pressure, revealed that recovery from 
long-duration space flight is prolonged compared to recovery following short-duration Space 
Shuttle missions. 
 
Limitations of Orthostatic Intolerance Reporting from Space Flight 
Early in the space flight program, almost all astronauts participated in some form of 
orthostatic tolerance testing, but in more recent years this has not been the case.  The 
incidence of orthostatic intolerance in Space Shuttle, Mir, and ISS astronauts has been 
gleaned primarily from scientific publications that specifically tested individuals or 
groups of astronauts in a controlled manner.  Due to the nature of these research projects, 
not all astronauts have participated, and therefore the results may not be entirely 
representative of the population of astronauts, cosmonauts, and other space flight 
participants.  Additionally, the perceived requirement for orthostatic intolerance testing 
has been diminished as the risk for orthostatic intolerance has been considered to be 
controlled with countermeasures (fluid loading, compression garments, cooling garments) 
during re-entry and the immediate post-flight period.  Further, in some cases, data from 
astronauts who could not complete a test after landing was excluded or not reported 
because hemodynamic data were not available.  Thus, the incidence of orthostatic 
intolerance among all astronauts, cosmonauts, and space flight participants may be under 
reported. 
 
Orthostatic tilt tolerance tests (OTT, 80° head-up tilt for 10 min or until presyncope) were 
implemented in the NASA program as a “standard measure” for Shuttle astronauts 
beginning in January of 1997 (STS-81) and in ISS astronauts beginning in October of 
2000 (Expedition 1).  In Shuttle astronauts, participation in these tests was required for 
first-time flyers and for individuals with previous orthostatic intolerance issues in earlier 
flights, at the discretion of the flight surgeon.  Testing was planned for landing day for 
Shuttle astronauts and for landing day or the first day of recovery for ISS astronauts 
(depending upon landing location and crew accessibility).  Additional testing also was 
planned during the recovery period but could be waived by the crew surgeon if this was 
not medically indicated. The OTT was terminated as a standard measure in Shuttle 
astronauts after STS-124 (June 2008) and  in ISS astronauts after Expedition 16 
(November 2007).  Preliminary results have been previously reported (2) but details of the 
testing protocols and results can be found in an upcoming manuscript to be published in 
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the journal of the Aerospace Medical Association, Aerospace Medicine and Human 
Performance, as a supplement describing the results of medical data collected during the 
first 10 years of ISS (Lee et al., Orthostatic intolerance after International Space Station 
and Space Shuttle missions.  Aviat Space Environ Med, In Press.).  That report contains 
results from 65 Shuttle and 20 ISS astronauts, two of whom (1 Shuttle, 1 ISS) were 
unable to participate in landing day testing for unspecified medical reasons.  An 
additional ISS crewmember was not well enough to participate in testing on the first day 
of recovery, even though most crewmembers demonstrate a significant amount of 
recovery within the first 24-48 h after landing. Three additional crewmembers were 
wearing all or part of the Russian Kentavr compression garment, consisting of two 
separate components covering the lower leg and the abdomen/thighs, when tested on R+0 
or R+1.  This might be interpreted liberally as an indication that the crewmember felt the 
need for cardiovascular support during the OTT. While this manuscript reports that there 
were some who could be considered to suffer from orthostatic intolerance that otherwise 
may not have been reported, a weakness of this dataset is that not all Shuttle 
crewmembers were required to participate, testing was terminated relatively early in the 
ISS experience, and many of the ISS astronauts were not tested until R+1.   
 
Additional data from ISS astronauts were not available until the inclusion of the 3.5-min 
stand test, first as part of the Functional Task Test (FTT) Study and more recently as part 
of the Pilot Field Test (PFT), a precursor to the Field Test Study. Shuttle astronauts 
completed the FTT stand test on landing day, but the ISS astronauts did not complete this 
test until the day after landing.  All Shuttle astronauts were able to complete this test on 
landing day (30), as were ISS astronauts 1 day after landing, albeit with a higher heart 
rate than preflight.  The PFT represented the first opportunity to collect stand test data on 
ISS astronauts immediately after landing and was implemented to collect a subset of the 
Field Test data collection while progressively removing logistical barriers to testing in the 
field within hours of landing.  PFT testing was scheduled to occur as many as 3 times 
during the first 24 hours after landing: (a) in a tent adjacent to the Soyuz landing site in 
Kazakhstan (~1 hour) or after transportation to the Karaganda airport (~4 hours); (b) 
during a refueling stop in Scotland (~12 hours); and (c) upon return to NASA Johnson 
Space Center (JSC) (~24 hr) after returning to Earth.  Preliminary results from the nine 
USOS astronauts to-date who were scheduled to participate in landing day PFT testing 
indicate that two were unable to complete the first test within hours after landing and the 
third was not able to participate until ~12 h after landing.  These crewmembers were 
wearing the Kentavr compression garment, yet 1/3 failed to complete testing within the 
first few hours after landing. However, further analysis of these results is indicated to 
clarify whether intolerance to standing in these individuals resulted from cardiovascular 
or neurovestibular dysfunction.  Data collection for the Field Test Study has been 
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initiated with the crew of the one-year mission and should yield more information, 
including the efficacy of the new graded compression garment (GCG). 
B. Fluid shifts and Plasma Volume 
 
Figure 9. Illustration of the changes in center of mass during spaceflight, from (31). 
When astronauts enter microgravity, a cephalad fluid shift occurs which invokes a reflex-
mediated hypovolemia. One of the first physiological changes noted during the Apollo program 
was the decrease in plasma volume, exhibited by the decrease in weight of the crewmen (32).  
One third of the average five percent weight loss was regained within 24 hours postflight, 
suggesting this fractional change was due to a loss of fluid. The remainder of the body weight 
loss was attributed to tissue loss, which is characterized by a longer recovery time(32).  Serum 
and urine samples were analyzed for endocrine and electrolyte changes from pre- to post-
spaceflight in order to better understand the etiology of the plasma volume losses of 4.4% upon 
return to Earth. The cephalad fluid shift and consequent fluid loss were thought to occur during 
the first two days of spaceflight, as seen in bed rest subjects. The smaller plasma volume loss in 
spaceflight was attributed to an elevated urinary aldosterone level upon landing.  Although the 
time course of the plasma volume losses was unknown due to the lack of inflight measurements, 
the degree of plasma volume loss was independent of the duration of the Apollo mission (32). 
Inflight anthropometric measurements during Skylab allowed for the determination of  time 
course and magnitude of fluid shifts. Photographs of the crewmen illustrated the commonly noted 
puffy faces and “chicken legs” exhibited during spaceflight as well as postural changes (31). 
Fluid shifts were further measured by anthropometric techniques and the determination of the 
center of mass.  
The effect of the cephalad fluid shift characteristic of spaceflight on the center of gravity is 
illustrated in Figure 9.   As in earlier missions, plasma volume losses were reported, but to a 
higher degree than in the Apollo program, with average losses of 8.4%, 13.1% and 15.9% for 
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Skylab 2, 3 and 4 (33). The time course of recovery from fluid losses can be seen in Figure 10. 
Blood volume analysis also showed a postflight decrease in red cell mass, which did not begin to 
reconstitute until at least 30 days postflight; this delay is suggestive of an inhibition of bone 
marrow (33).  
 
Figure 10. Plasma volume losses following three Skylab missions (33). 
In 1985, consuming fluid and salt prior to landing (fluid loading) became a medical requirement, 
thus any data on plasma volume acquired after this date do not capture the true landing day 
plasma volume deficit.  In spite of the fluid loading, astronauts return from space with plasma 
volume deficits ranging from 5 to 19% (4–6,14,34).  Additional confounding factors to accurate 
measurement of spaceflight-induced plasma volume loss include ad lib water ingestion following 
landing and IV fluid therapy that is given to the more severely affected crewmembers.   
The mechanism of the plasma volume loss has been a matter of some debate (35).  There 
have been limited inflight studies of plasma volume.  One study shows a decrease in total body 
water during flight, suggesting but not proving a dieresis (36).  A second study shows a decrease 
in plasma volume, but an increase in intracellular fluid, suggesting “3rd spacing” and not a 
diuresis (34); however, postflight studies from the Apollo (32) and EDOMP (37) programs do not 
show an increase in the intracellular fluid compartment.  These disparate flight data reinforce the 
need for further flight studies (which are in progress as of this revision)..  
Similar plasma volume losses (4 – 17%) have been replicated using 6º head-down tilt bed rest 
as an analog to spaceflight (32,39). Most of the loss occurs within the first week, and plasma 
volume remains stable for the duration of bed rest.  Recent bed rest studies have shown a 
markedly increased urine excretion upon bed rest (38,39).  Further study into this effect during 
spaceflight is needed and is considered a research gap.   
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C. Cardiac Atrophy 
 
Cardiac muscle is responsive to changes in volume loading conditions. Decreased cardiac 
work during bed rest due to plasma volume loss, reduced LVEDV, and reduced physical activity 
results initially in smaller cardiac volumes and later remodeling to a smaller cardiac muscle mass.  
Assumption of the head-down position increases stroke volume with a concurrent decrease in 
heart rate, with the highest stroke volumes achieved ~30 minutes after the start of bed rest.  
Thereafter, resting stroke volume decreases with the lowest value obtained by ~48 h and remains 
depressed throughout the end of bed rest (Figure 11) (10).  Though head-down bed rest initially  
 
 
Figure 11. Stroke volume, heart rate, and total peripheral resistance measured during 14 d of 6° 
head-down bed rest (10). 
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results in a cephalic shift of ~1 liter of blood from the legs to the upper torso, this is counteracted 
by humoral responses leading to diuresis and attainment of hemostasis at a level approximately 
half way between supine and upright about 24 to 48 h after the start of bed rest (10). 
After 2 weeks of 6 head-down tilt bed rest, cardiac mass and LVEDV measured by 2-d 
echocardiography was decreased by 5% (p<0.10) and 7% (p<0.05), respectively (10).  This was 
concomitant with a 24% decrease in LBNP tolerance measured using a ramp protocol.  Longer 
duration bed rest results in further cardiac atrophy.  LV mass is reduced in men by 4.7, 8.0, and 
15.6% after 2, 6, and 12 wk, respectively, of horizontal bed rest (11).  Sixty days of 6° head-down 
bed rest resulted in decreased LV mass of 9.5% in women, which lies along the same line 
describing the relation between changes in LV mass and bed rest duration in men (40).  
Importantly, reduced ventricular volume precedes cardiac muscle atrophy.   For example, 
LVEDV was decreased by 2 weeks of bed rest, but LV mass was not reduced (as measured by 
MRI) until 6 weeks (Figure 12). Thus, the LV mass-volume ratio is initially reduced, followed by 
cardiac remodeling in response to decreased wall stress (11).  Similar results have been obtained 
from measurements of the right ventricle, although the changes ventricular volume and mass 
perhaps are less dramatic (11,40). 
 
 
Figure 12.  Change in LVEDV and LVM as a function of bed rest duration.  Bed rest results in a 
comparatively rapid and more profound decrease in LVEDV by a decrease in LVM.  Data from 
(10,11,40–42) 
 
The decrease in cardiac mass is concomitant with a reduced stroke volume at any given 
filling pressure.  In the supine resting condition, after two weeks of bed rest pulmonary capillary 
wedge pressure (PCWP) and LVEDV are decreased by 18% and 7%, respectively (10).  Starling 
Curves, constructed from PCWP and SV measures during LBNP and with rapid warm saline 
infusion, indicated a change in the cardiac distensibility, particularly at lower filling pressures 
(Figure 13).  Pre- to post-bed rest, PCWP was not changed during -15 mmHg and -30 mmHg of 
LBNP, yet SV was reduced.  Surprisingly, the relation between LVEDV and SV was unchanged, 
suggesting that this duration of bed rest had no effect on cardiac contractility (same SV per 
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LVEDV); lower SV after bed rest resulted from a decrease in diastolic volume.  Thus, there is a 
leftward but parallel shift in the filling pressure-volume relation after bed rest.  In total, bed rest-
induced changes in cardiac distensibility leads to lower LVEDV and reduced SV at filling 
pressures representative of low levels of orthostatic stress.  The decreased distensibility is 
reflected in a decrease in left ventricular untwisting during diastole (42).  Assuming that reduced 
cardiac distensibility continues to parallel the progression of cardiac atrophy with longer bed rest 
durations, a progressive decrease in diastolic function would be one contributing factor to the 
decreased stroke volume during orthostatic stress and increasing frequency of orthostatic 
intolerance (11). 
 
 
Figure 13.  Starling Curves constructed from PCWP and SV measured at rest, during LBNP (-15 
and -30 mmHg) and with rapid warm saline infusion (15 and 30 ml/kg) before and after 2 weeks 
of bed rest (10). 
 
That these changes in diastolic cardiac performance result from cardiac remodeling, rather 
than just bed rest-induced hypovolemia, is supported by the work of Perhonen et al. (41).  
Subjects were studied before and after 18 day of bed rest as well as before and during 
furosemide-induced hypovolemia to compare changes in diastolic cardiac performance within the 
same subjects.  Though bed rest and furosemide resulted in similar losses of PV (-15% vs. -14%), 
LVEDV during supine rest was decreased by almost three times as much after bed rest as by 
hypvolemia (-20 vs. -7%) while PCWP at rest decreased by only ~50% more (-21 vs. -31%) after 
bed rest than during hypovolemia.  Further, both bed rest and hypovolemia resulted in changes in 
the linear portion of the Starling Curves (PCWP-SV, from baseline rest through LBNP at -30 
mmHg), but the slope of the relation was increased approximately twice as much after bed rest as 
during hypovolemia.  Additionally, while bed rest resulted in a leftward shift of the pressure-
volume relation (PCWP-LVDV), there was no change in this relation during hypvolemia.  While 
the reduction LBNP tolerance after bed rest only tended to be more than during hypovolemia (-27 
vs -18%), the combination of bed rest-induced cardiac remodeling and plasma volume loss 
resulted in more dramatic changes in diastolic cardiac function than hypovolemia alone.   
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Thus, it is not surprising that attempts to restore blood and plasma volume status by fluid 
loading during space flight (43) have failed to fully prevent orthostatic intolerance.  Even 
restoring filling pressures in the face of decreased cardiac distensibility will not prevent the 
reduction in stroke volume (10,41).  Conversely, Shibata et al. (44) report that maintaining 
diastolic function alone through supine cycle exercise fails to prevent post-bed rest orthostatic 
intolerance.  The results of their work suggests that a combination of fluid loading (through 
intravenous catheter) and exercise are necessary.  Similar results were obtained by Hastings et al. 
(45) in subjects who combined rowing and resistive exercise throughout bed rest with two days of 
fluid loading accomplished through fludrocortisone and increased salt intake. 
D. Autonomic function  
 
Figure 14.  Comparison of plasma volume losses between short 
duration spaceflight and long duration spaceflight (1). 
 
 It has been shown, however, that postflight orthostatic hypotension and presyncope are not 
dependent on the degree of postflight hypovolemia alone (5,6). Figure 14 shows that plasma 
volume losses are similar between long duration and short duration crewmembers. However, long 
duration crewmembers experience a higher rate of presyncope than short duration crewmembers .  
Also, in a recent study, Waters et al (6) reported on two groups of male short duration astronauts.  
One group had a 7.1% plasma volume loss on landing day and did not become presyncopal 
during tilt testing; whereas, the other group also had a 7.1% plasma volume loss, but did become 
presyncopal.  The difference between groups was that the non-presyncopal group had hyper-
adrenergic responses to tilt and the presyncopal group did not (Figure 15).  
Postflight data measuring muscle sympathetic nerve activity in six non-presyncopal male 
astronauts (46) also shows that sympathetic responses in these crew members are appropriate  
These data are supportive of the norepinephrine spillover studies mentioned above. 
Unfortunately, there were no presyncopal subjects in this study and the postflight sympathetic 
dysfunction in that group of astronauts could not be duplicated  
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.  
Figure 15.  Plasma norepinephrine responses in women (n= 4; black bars), presyncopal men (n= 6; 
light gray bars), and nonpresyncopal men (n =22; dark gray bars) when tested preflight (left), on 
landing day (right) (6).    
 
Furthermore, astronauts who experienced both short and then long duration spaceflight were 
more likely to have a hypo-adrenergic response and become presyncopal during tilt testing after 
the long duration flight despite similar plasma volume losses in both flights (1). Thus, it is not the 
plasma volume loss alone that causes presyncope, but the lack of an adequate physiological 
response to the hypovolemia. 
Heart rate variability (HRV) and blood pressure variability provide a means to noninvasively 
approximate autonomic activity through analysis of fluctuations in the R-R interval and SBP data. 
In particular, the high frequency component of the R-R interval series (HF-RR), in absolute or 
normalized units, is an index of parasympathetic modulation (47–49), and the low frequency 
component of the SBP (LF-SBP) approximates sympathetic activity (47,50–52).  The 
interpretation of the low frequency to high frequency ratio of the R-R interval (LF/HF-RR) is 
more controversial. The LF/HF-RR is often used as a marker of sympathovagal balance 
(47,49,50,53). However, this interpretation has been challenged by studies that question the 
concept and construction of the index (54), suggest variation in the LF/HF-RR is partially due to 
changes in baroreflex function (55), or conclude that spectral HRV is mainly a measure of 
parasympathetic activity (56).   
 
Most studies examining HRV in bed rest have found a decrease in HF-RR during bed rest or 
immediately afterwards (57–60). This bed rest-induced decrease in HF-RR has additionally been 
evident in bed rest as short as 20 hours with a furosemide infusion (61), during a controlled 
breathing protocol (22,23), during LBNP (62), and during vasoactive drug infusions (63). Despite 
some finding no difference in HF-RR with bed rest (64,65), it is well accepted that the HRV 
results indicate diminished vagal modulation after bed rest. The majority of studies that examined 
LF/HF-RR as either an index of sympathovagal balance or an indicator of sympathetic activity, 
found LF/HF-RR increased with bed rest (22,23,57,59,61,62,66). However, this increase in 
sympathovagal balance is not as explicit as the decrease in vagal modulation, since other studies 
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did not find LF/HF-RR to change with bed rest (60,65,67). It should be noted that (65) only 
studied a 24-hour bed rest, such that autonomic changes that become significant after the first 24 
hours would not be detected. Approximation of sympathetic activity by blood pressure variability 
has yielded incongruent results, with increase (52,61,63), no change (22,59,64), and decrease 
(23,58) in LF-SBP occurring after bed rests of various durations. 
 
Other measures of HRV do not have established links to autonomic activity, but can quantify 
overall variability or complexity. When studied throughout bed rest, these measures indicate that 
the total variability and complexity of heart rate decrease with bed rest. The total power in power 
spectral analysis of R-R interval quantifies the overall variability, and has been shown to decrease 
in bed rests ranging from 28 to 90 days (57,60,62,64). Heart rate complexity cannot be quantified 
by typical spectral analysis techniques such as methods based on the Fast Fourier Transform. 
Instead, coarse grain spectral analysis (CGSA) (68) can be used to extract the harmonic and 
fractal components of HRV and characterize the complexity of HRV by the exponent of the 1/f 
noise in the signal. This exponent corresponds to the slope of the linear fit of the fractal 
component plotted in a log-power vs. log-frequency scale. The spectral exponent has been found 
to increase with bed rest (57,69), indicating a steeper power drop-off at higher frequencies and a 
decrease in heart rate complexity. Heart rate complexity has also been shown to decrease with 
bed rest when measured by approximate entropy, which quantifies the predictability of 
fluctuations in heart rate (67). 
 
In summary, the majority of the studies indicate that bed rest causes autonomic dysfunction 
by diminishing vagal modulation, increasing sympathovagal balance, and decreasing the overall 
variability and complexity of heart rate. The effect of bed rest on the approximation of 
sympathetic activity by blood pressure spectral analysis is not clear due to conflicting results.  
Analysis of the heart rate and blood pressure series can further yield information on 
baroreflex sensitivity. Baroreflex sensitivity has been broadly shown to decrease with bed rest, as 
measured by examining the maximum slope of the baroreflex curve (15), beat-to-beat sequences 
of R-R interval and SBP (21,58–60,62–64,66), or the transfer function between the R-R interval 
and SBP  (22,23,58,70). Iwasaki et al. attributed the decrease in baroreflex sensitivity after a 14-
day bed rest to hypovolemia, due to a reversal of the baroreflex change after plasma volume 
restoration. However, Arzeno et al. (63) found that the decrease in baroreflex sensitivity after a 
60-day bed rest was not due to decreased plasma volume. 
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Figure 16. Gender-specific orthostatic response to 
spaceflight.   Women (6 astronauts, 5 non-pilots) are 
much more likely to become presyncopal than their 
male cohorts (30 astronauts, 12 non-pilots), even when 
pilots, a self-selecting, highly trained subset, are 
removed from the analysis. 
The bed rest-induced autonomic and 
baroreflex dysfunction can contribute to 
post-bed rest orthostatic intolerance, and 
pre-bed rest indices of autonomic function 
may help identify those at higher risk of 
post-bed rest orthostatic intolerance. In 
particular, Convertino et al. (15) found 
presyncopal subjects suffered a larger 
decrease in baroreflex sensitivity during bed 
rest, and Pavy-Le Traon et al. (62) found 
presyncopal subjects to have a smaller 
increase in LF/HF-RR during LBNP. 
 
E. Sex differences  
 
The vast majority of astronauts have 
been male and, consequently, any 
conclusions drawn regarding the 
physiological responses to spaceflight are 
male-biased.  NASA has recognized that 
there are some significant differences in how men and women respond to spaceflight (71), 
including sex differences in the effects of spaceflight on cardiovascular responses to orthostatic 
stress (6).  Historically, greater than 80% of female crewmembers become presyncopal during a 
postflight tilt test (6) compared to about 20% for men (Figure 16).   
As in spaceflight, a very low number of female subjects are studied during bed rest.  This is 
traditionally done to reduce the variability in the data and to eliminate the scheduling issues 
related to the menstrual cycle.  However, women have also been found to be more susceptible to 
orthostatic intolerance than men after head-down tilt bed rest (72).  This gender difference, which 
is often seen even before bed rest, is illustrated in the survival analysis published by Grenon et al. 
(Figure 1717).  
The gender 
difference in 
propensity to 
orthostatic 
intolerance, 
observed during 
both spaceflight 
and bed rest, leads 
to an important 
consideration for 
Figure 17. Presyncopal survival (15 females, 14 males) following head‐down tilt 
bed rest.  From  Grenon et al [3]. 
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countermeasure development, as a single countermeasure is not likely to be equally effective for 
both genders.  This hypothesis has been confirmed by Grenon et al. (72) when they showed that 
midodrine was less effective in preventing orthostatic intolerance in women than men following 
simulated microgravity. 
 
The incidence of orthostatic intolerance has been shown by several investigators to be higher in 
women than in men (6,73–77), and, though the etiology has not been exactly determined, many 
studies have identified potential contributory factors that differ between the sexes.  Waters et al. 
(6) nicely summarizes some of the possible reasons sex differences may cause the disparity in 
orthostatic tolerance.  Women have greater heart rate responses than men during mental stress 
(78), standing (74,79) , infusions of pressor agents (80), and cold pressor tests (81).  It also has 
been shown that estrogen replacement therapy in postmenopausal women reduces muscle 
sympathetic nerve activity (82,83).  
These differences in response to stress can be partially due to a dissemblance in autonomic 
regulation between the genders.  Women are often characterized by attenuated sympathetic 
response and enhanced parasympathetic reactivity, particularly during orthostatic stress 
(72,76,84–88).  These gender differences in autonomic dominance have been observed during tilt 
and stand tests (72,76,85,86,89), lower body negative pressure (LBNP) (88), autonomic blockade 
(84), and vasoactive drug infusions (63).  Differing brain activity patterns during LBNP (90) and 
task performance (87) can provide some insight into the distinctions in autonomic response, but 
more studies are necessary to exactly determine the cause of these gender differences.  The 
autonomic control differences between the genders are preserved throughout bed rest, with 
women also experiencing a decrease in baroreflex sensitivity within a shorter time-frame than 
men (63). 
In addition, differences in vascular resistance and reactivity can contribute to the gender 
difference in orthostatic intolerance.  Women have smaller increases in vascular resistance than 
men in response to LBNP (77,91), standing (92), cold pressor and facial cooling tests (93), and 
mental stress (94).  Women may also have lower orthostatic tolerance because of increased 
splanchnic blood flow compared to men (75,95) due to attenuated splanchnic constriction in 
women in the upright posture (96).  The attenuated vascular constriction in women has also been 
observed as attenuated brachial and femoral vasoconstrictor responses to increases in transmural 
pressure (97).  There could be several factors that contribute to the women’s low vascular 
resistance, the most important of which is probably estrogen.  Several studies in humans 
demonstrate an augmentation of endothelium-dependent vasodilation with estrogen (98–102).  
Low peripheral vascular resistance is considered one of the main drivers for post-spaceflight 
orthostatic intolerance (6).  Arterial stiffness is another potential contributor to post-spaceflight 
orthostatic intolerance. An increase in arterial stiffness after spaceflight has been linked to 
orthostatic tolerance in men (103).  However, despite men experiencing increases in arterial 
stiffness after spaceflight and bed rest, no significant increase in arterial stiffness has been 
observed in women (104). 
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The aforementioned differences between the genders focus on the autonomic response to 
orthostatic stress and changes in heart rate and vessel reactivity.  However, decreased cardiac 
filling also contributes to the higher incidence of orthostatic intolerance in women.  Fu et al. (73) 
showed that women had lower tolerance to LBNP, most likely due to a steeper Frank-Starling 
relationship.  They found that women had larger decreases in stroke volume in response to 
decrements in cardiac filling pressure compared to men and suggested that this smaller and stiffer 
left ventricle is the primary reason for the propensity of women to have decreased orthostatic 
tolerance. 
   
F. Ground  
 
Figure 18. Tracings during a tilt test  from a patient with autonomic failure (A), and an 
astronaut preflight (B) and on landing day (C). Horizontal bars are the time in upright 
posture (4) 
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In 2004, slightly over 164,000 patients were hospitalized in the United States with a diagnosis 
of orthostatic hypotension (105).  Causes of these hospitalizations ranged from simple volume 
depletion to autonomic failure.  Previous work has shown that the pattern of post-spaceflight 
orthostatic intolerance is similar to that seen in patients with autonomic failure (Figure 18) (4).  In 
fact the countermeasure midodrine was proposed due to its use for this purpose.  Studies that 
involve ill subjects tend to make extrapolation to the astronaut corps difficult, thus a model that 
includes otherwise healthy individuals is preferable.  Figure 18 shows the similarities between 
clinical orthostatic hypotension in a patient with adrenergic failure and post-spaceflight 
orthostatic hypotension.  Before spaceflight, the astronaut exhibits normal responses to standing: 
blood pressure is stable and heart rate increases slightly.  This crewmember had no symptoms of 
orthostatic hypotension, had increased norepinephrine release by 236 pg.ml and completed the 
full stand test.  Following spaceflight, however, the same crewmember exhibited classic signs of 
orthostatic intolerance during the stand test (Figure 18C).  Systolic blood pressure decreased 
when the astronaut stood and heart rate increased markedly, without any increase in 
norepinephrine release.  After ~ 2 minutes of standing, systolic pressure decreased below the 
termination threshold and the test was stopped.  This pattern of orthostatic intolerance is 
amazingly similar to that of the adrenergic failure patient shown in Figure 18A.  These 
similarities suggest that clinical research into adrenergic failure would be extremely useful in 
developing countermeasures to spaceflight-induced orthostatic intolerance.   
Similarly, current pharmacological treatments for adrenergic failure may have application to 
spaceflight-induced orthostatic intolerance.  Indeed, midodrine is FDA approved for orthostatic 
hypotension due to adrenergic failure and is discussed in depth under the countermeasure section.  
Such research done at NASA may also benefit the larger clinical community.  Again using 
midodrine as an example, we uncovered a drug interaction between midodrine and promethazine 
that was previously unpublished (106). Healthy test subjects who received midodrine and 
promethazine together experienced a higher incidence of akathisia than controls or subjects with 
either drug alone.  Anecdotal reports from emergency room physicians report similar symptoms 
in patients with diabetic neuropathy who present with nausea and are given promethazine while 
being treated for hypotension with midodrine.  In the future, the knowledge of this interaction can 
help avoid unnecessary patient distress and hospital admissions in clinical practice.  
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1. Hypovolemia 
 
 
 
Figure 19.  Norepinephrine responses of presyncopal (n=8) and nonpresyncopal (n=9) test 
subjects during normovolemia and hypovolemia tilt tests 
Laboratory models of hypotension may illuminate the phenomenon in astronauts.  Several 
investigators have used pharmaceuticals to induce a plasma volume loss similar to that of 
spaceflight.  Kimmerly and Shoemaker used three days of spironolactone administration to 
induce a 15.5 ±1.7% decrease in plasma volume (107,108).  While this model was useful for their 
purposes, spironolactone is known to have vasomotor effects, which complicate interpretation of 
studies involving integrated cardiovascular responses.  Fu et al. used a single dose of Lasix®, 
which decreased plasma volume by ~13% to study the effects of acute hypovolemia on 
orthostatic tolerance (109). Their results showed that orthostatic tolerance, as induced by LBNP, 
was markedly decreased in women, but not men, during hypovolemia; but they did not find any 
differences in norepinephrine responses between genders or between normovolemia and 
hypovolemia.  Iwasaki et al. also used a single dose of Lasix®  and found that the effects on 
cardiac filling pressures, stroke volume and high-frequency  baroreflex sensitivity were similar 
between hypovolemia and two weeks of head-down tilt bed rest; however, they also found that 
vasomotor function differed between the two protocols.  Finally, Meck et al. have used a single 
Lasix® (furosemide) infusion (0.5 mg/kg) followed by 36 hours of a very low sodium diet (10 
mEq/day).  This protocol induces a plasma volume loss similar to that after spaceflight (4–6,14).  
Those who became presyncopal after spaceflight and during hypovolemia exhibited the same 
etiology, a failure to release the extra amount of norepinephrine necessary to maintain standing 
arterial pressure when hypovolemic (Figure 19).  The differences in these studies may be due to 
the hypovolemia protocol (acute vs. chronic) or in the orthostatic stimulus (tilt vs. LBNP).  
Regardless of these differences, pharmacologically-induced hypovolemia has been shown to 
reproduce the plasma volume losses seen following spaceflight.  While obviously useful for some 
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mechanistic studies and countermeasure development, this model is limited in that the disuse 
(deconditioning) component of spaceflight (and bed rest) is not replicated. 
 
2. Bed rest 
Bed rest studies, particularly those at 6° head-down tilt, are traditionally used as the best 
ground-based analog to spaceflight.  An excellent review by Pavy-Le Traon et al. describes these 
similarities (7), including changes in plasma volume and orthostatic tolerance that occur after 
only a few days of head-down tilt bed rest (Table 1).  
 
Table 1.  Comparison of spaceflight and head down tilt bed rest (7). 
 
A summary of bed rest studies showing changes in physiological measurements that 
contribute to orthostatic intolerance can be found in Table 2.  All bed rest studies listed here, 
except one, report plasma volume losses in excess of 8%.  With the exception of the Shoemaker 
study (110), stroke volume was shown to decrease and total peripheral resistance to increase.  
Heart rate was less consistent, although the majority of studies report increases in heart rate at rest 
and following an orthostatic challenge.  These findings are very similar to those seen following 
spaceflight  
Most of the recent bed rest studies have focused on elucidating the mechanisms of orthostatic 
hypotension.  These mechanisms include cardiac atrophy, sympathetic dysfunction, arterial and 
venous alteration, etc.  Numerous publications have shown a cardiac atrophy following bed rest 
(10,11,23).  Levine and co-workers found that 14 days of head-down tilt bed rest results in a 
smaller, stiffer left ventricle, leading to a decrease in stroke volume (10).  This decrease in 
ventricular volume and stroke volume is similar to that found by Arbeille, et al. (111) and others 
and is thought to be due to the decrease in myocardial workload that is experienced in bed rest as 
well as spaceflight.  These investigators conclude that the decrease in stroke volume is a primary 
contributor to orthostatic intolerance. 
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Table 2.  Summary of bed rest studies showing orthostatic tolerance. From Waters et al.  (112). 
 
Many studies have shown that there is a disruption in the way the autonomic nervous system 
regulates the cardiovascular system following bed rest.  Eckberg and Fritsch (18) and Convertino 
(15) showed decreases in baroreflex gain following short duration bed rest, which indicates a 
dysfunction in the carotid baroreflex.  Muscle sympathetic nerve activity (MSNA) has been 
studied as an indicator of the signal sent from the nervous system to the blood vessels 
(sympathetic tone); however, there have been conflicting results from this research.  Kamiya et al. 
(113) studied male subjects after 120 days of head-down tilt bed rest.  During a graded tilt test (30 
and 60 degrees), MSNA was measured in the tibial nerve.  Resting MSNA and heart rate were 
higher following bed rest and baroreflex slopes for MSNA were steeper during tilt following bed 
rest, but there were no presyncopal subjects following this prolonged bed rest.  The authors 
concluded that the augmented MSNA response increased vasomotor tone and prevented 
presyncope.  In a follow-up study, these same authors studied 22 male volunteers before and after 
14 days of bed rest (114).  In this study, 10 subjects became presyncopal during post-bed rest tilt 
testing.  In the hypotensive subjects, MSNA was lower throughout the tilt and was suppressed 
during the last minute of tilt.  This pattern was not seen in the subjects who were able to complete 
the tilt test.  These subjects responded similarly to their previous study.  These data directly 
support the data that show a decreased norepinephrine response during postflight tilt testing.  
Pawelczyk et al. (115) also measured MSNA following bed rest.  In this study LBNP was used as 
an orthostatic stress.  They found that MSNA was increased during LBNP following bed rest; 
however, this response was appropriate given the changes in stroke volume and cardiac filling 
pressure and thus reflex control of MSNA was not altered.  These data highlight the difficulty in 
comparing bed rest studies. 
Finally, vascular function, whether arterial or venous, has been shown to be modified after 
bed rest.  In the review paper by Pavy-Le Traon(7), the authors stress that the inability to 
sufficiently increase peripheral resistance is an important factor in the etiology of post-spaceflight 
and post-bed rest orthostatic intolerance.  This points not only to the importance of the 
sympathetic nervous system, but also the vasculature.  Lower limb arterial resistance has been 
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shown to decrease during head-down tilt bed rest as well as spaceflight, but carotid artery 
resistance did not change.   
Nitric oxide (NO) has been hypothesized to contribute to orthostatic intolerance through its 
effects on the vascular smooth muscle  Bonnin et al. (116) showed that flow-dependent dilation of 
the brachial artery was increased following seven days of bed rest and that this increase was 
negatively correlated to post-bed rest orthostatic tolerance.  There was no change in the response 
to nitroglycerin, implying an endothelium-dependent (for example, NO) effect.  Bleeker et al. 
(117) did a similar study in the femoral artery following horizontal bed rest.  They found 
augmented arterial dilation in response to flow and nitroglycerin, implying an endothelium 
independent mechanism, likely an increased sensitivity to NO in the vascular smooth muscle.  It 
is known that different vascular beds respond differently to the same stimuli, which may explain 
these differences.   
Taken as a whole, these studies may seem disparate, but upon careful examination they all 
point to a decreased venous return as critical to the development of orthostatic intolerance.  
Similar mechanisms are likely at play during spaceflight and help inform future countermeasure 
development.   
Limitations in the current literature are highlighted in Table 2, the most obvious of which is 
the lack of standardization in the bed rest protocols.  The number of days in bed rest varies from 7 
to 42 days, and a standardized protocol in use in the current NASA bed rest project includes 90 
days of bed rest.   
G. Animal models 
 
Studies designed to examine the effects of the spaceflight environment on human physiology 
have benefited greatly from the use of non-human models. Indeed, considerable advances in 
knowledge have been gained from investigations employing animals. In addition to elucidating 
the physiological consequences of weightlessness, animal research has proven to be a cost 
effective platform for elucidating biological mechanisms responsible for such adaptations and 
toward countermeasure development. The hind-limb suspension rodent (HLS) model in particular 
has been widely used to study microgravity alterations in skeletal muscle (118–120) and 
bone/calcium regulation (121–124). The use of the HLS model may not be valid for all aspects of 
spaceflight research and, as with all models certain limitations exist when extending results to 
explain human physiological adaptations. Nonetheless, many of the biological and physiological 
changes in these animals appear similar to those in humans exposed to weightlessness. For 
example, this model reproduces the cephalad fluid shift that occurs during spaceflight which is 
central to the cardiovascular deconditioning hypothesis underlying post-spaceflight orthostatic 
intolerance (125–127). Given the physiologic similarities between the HLS and actual human 
spaceflight adaptations, there has been increased interest in its use to explain the mechanisms of 
cardiovascular deconditioning as they relate to orthostatic intolerance.  
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Cardiovascular Control 
Considerable evidence exists which supports the hypothesis that while hypovolemia is likely 
the primary initiator of the cardiovascular dysfunction which occurs with spaceflight, it is not the 
only cause that underlies the cardiovascular impairment in orthostatic intolerance. The 
importance of interplay between components of the cardiovascular system should not be 
overlooked, however a significant strength of the animal research performed to date is the ability 
to examine individual components of the cardiovascular system control. 
 
Vascular Regulation. Many of the theories underlying the orthostatic intolerance in astronauts 
point to a significant vascular component which includes differential remodeling of blood vessels 
in the upper compared to lower body and which may accompanied by alterations in endothelial 
dependent and independent control of vascular function. A succinct summary of many of the 
vascular adaptations that occur in animals exposed to spaceflight and HLS has previously been 
published and the reader is referred to this paper (128). The primary goal of this section is to 
review some of the more recently published data that have advanced not only our understanding 
of mechanisms of orthostatic intolerance but may reveal additional insight into areas that have 
overlapping vascular etiologies. 
 
It is widely accepted that the inability to elevate peripheral vascular resistance following 
spaceflight explains, in part, the orthostatic hypotension experienced by many astronauts. Earlier 
research indicate that lower body peripheral resistance vessels have a larger cross-sectional area 
(increased capacitance) (103) and a diminished ability to constrict following exposure to 
simulated microgravity (129). Furthermore, in arteries from non-posture related muscles, the 
lower constrictor function is related to a blunted response to vasoconstrictor stimuli (130,131) and 
reduced myogenic tone (132). Current countermeasures, such as the Russian Kentaver and the 
NASA anit-gravity suit, have been developed to reduce the pooling of blood in lower limbs and 
thus help elevate peripheral resistance upon return to Earth’s gravity. While a great deal of 
research has been focused on understanding and overcoming the cardiovascular deconditioning 
effects of the vasculature in the lower body, recent evidence suggests that changes in cerebral 
vascular conductance may also contribute to the incidence of orthostatic intolerance in astronauts. 
 
Cerebral Blood Flow. Often overlooked, but critically important to orthostasis is the 
maintenance of cerebral circulation. In general, cerebral blood flow is well protected against 
systemic changes in pressure and flow without compromising the high demands of brain tissue. 
Unfortunately, few spaceflight studies have been designed to examine the role of cerebral blood 
flow and cerebral autoregulation in humans. Much of the data which does exist argues against 
changes cerebral autoregulation and do not provide evidence for changes in vascular function. For 
example, Fritsch-Yelle et al. (4) measured blood flow velocity in the middle cerebral artery using 
ultrasound but did not find a difference in tilt response between presyncopal and nonpresyncopal 
astronauts. In a similar study, measures of cerebral blood flow, velocities, and beat-to-beat 
changes in arterial pressure were collected before and after 16 days in space. The authors of this 
study maintained that static autoregulation was not impaired and dynamic regulation was actually 
improved (133). Greaves et al. reported similar findings in subjects following 60 days of HDT 
bed rest (134). 
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While the human data appear undisputable, evidence from several ground-based studies using 
the rat hind-limb tail suspension model suggests that the reduction in cerebral blood flow is 
associated with a decrease in autoregulation and that it is due to alterations in cerebral arterial 
structure and function. Indeed, data from Geary et al. (135) and Wilkerson et al. (136,137) 
indicate that myogenic tone and vascular resistance is increased, and that the difference in tone 
(suspended versus control rats) is related to changes in nitric-oxide-mediated vasodilation. 
Interestingly, the overall functional consequence of increased tone appears to lead to reduced 
blood flow and the stimulus does not appear to be an increase in arterial pressure but rather 
increases in transmural pressure caused by the elevation in the extravascular pressure in the 
cranium (136). 
 
H. Computational Modeling and Simulation 
 
1. Mechanisms of Orthostatic Intolerance Inferred from Models and 
Simulations 
 
Computational modeling has been leveraged by NASA since the 1970s for simulating post-
flight orthostatic stress, as well as in spaceflight analog conditions including head-down tilt 
(HDT) bed rest, lower-body negative pressure (LBNP), head-up tilt (HUT) and water immersion 
experiments (138–147). Most of these models were lumped parameter systems models based on 
the Guyton circulation model (148) or the Croston cardiovascular control model for acute 
simulations (149). The models that were derived from the Guyton model were used for simulating 
time-averaged chronic adaptation of the cardiovascular system, including fluid balance and fluid 
regulation, to various perturbations such as HDT. The models derived from the Croston model, 
on the other hand, were used for simulating beat-by-beat short-term responses of the 
cardiovascular system. All of the computational models were mostly qualitatively validated 
against experimental data acquired from spaceflight, LBNP, HUT, head-HDT bed rest and water 
immersion studies. The validation studies typically focused on overall response of the 
cardiovascular system with respect heart rate (HR), cardiac output (CO), stroke volume (SV), 
mean arterial pressure (MAP) and blood volume (BV).  
One particular simulation study performed by NASA (150) used a model developed by 
Croston and Fitzjerrel (1974) (151) which was designed for simulating dynamic response of the 
cardiovascular system to LBNP and HUT on a beat-by-beat basis.  Given that the LBNP portion 
of the model was developed for a supine subject, it was most suited for microgravity simulations. 
Therefore, the LBNP simulation capabilities were modified for microgravity analysis. However, 
the LBNP simulation was very sensitive to changes in total BV, which was not directly measured 
during flight. Consequently, in-flight BV levels had to be calculated or estimated through various 
methods.  
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The model was also limited by the 
fact that it was designed to simulate 
short term response (minutes) and it 
represented the cardiovascular system 
as a closed loop system. To overcome 
these limitations, White et al. (1983) 
integrated the LBNP model with the 
Guyton model so that the Guyton 
model re-initialized the LBNP model 
by controlling the fluid intake, fluid 
output and volume of red blood cells at 
the end of each short-term LBNP run. 
The performance of the modified model 
was validated against a number of flight 
studies, summarized in Figure 20 and 
Error! Reference source not found.3. 
As a demonstration of how models 
can be used for hypothesis testing, the 
authors performed two postulated 
analyses for long term effects of 
spaceflight on vasculature.  The first 
postulated condition was based on clinical findings that suggested prolonged partial collapse of 
the leg veins due to cephalic shift of blood may result in re-toning of vasculature to accommodate 
the reduced BV in the legs and to maintain near normal venous pressure. This hypothesis was 
formulated within the model by shifting leg compliance curves as a function of leg BV changes 
with time. In conjunction with the first hypothesis, it was also postulated that the eventual 
reduction in total BV would be equal to the amount that migrates from the legs to the upper body. 
This hypothesis was represented in the model by setting the history of the leg BV reduction equal 
to the history of the total BV reduction. The simulation was then executed in accordance to a 
Skylab in-flight LBNP protocol used on one crewmember on mission day 52. A comparison of 
the simulation results with the Skylab data showed similar trends (Figure 21), with the strongest 
correlation existing for the hypothesis regarding vascular re-toning in the lower limbs as a 
consequence of BV reduction in the legs (upper plot in Figure 21).  
Table 3: Validation comparison of modified LBNP model with available 
experimental data (reproduced from White et al. (150)) 
Changes 
from rest LBNP Model 
Data Source 
Apollo crew 
preflight av. 12 
subjects 
Hovey (1972) 
Musgrave 
paper (1971)
Wolthuis 
paper 
(1970) 
Skylab crew 
preflight av. 6 
subjects Johnson 
(1972) 
Increase in heart 
rate (heats/min)
-30 7.3 4.4 
8.0 11.89 
 
-40 9.8 8.9  
-50 15.1 14.6 10.5 
Decrease in -30 12.0   18.62  
Figure 20: LBNP simulation results compared with 
pre-flight crew average data for Apollo and Skylab (from 
White et al. (150)). 
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stroke vol. (ml) -40 16.0   
-50 23.0   
Decrease in 
systolic press. 
(mmHg) 
-30 4.8  
7.0 6.61 
 
-40 7.5   
-50 10.9  9.0 
Increase in 
diastolic press. 
(mmHg) 
-30 -0.4  
-3.5 0.16 
 
-40 -0.6   
-50 +0.2  0.36 
Increase in leg 
blood vol. (ml) 
-30 274  
614 419* 
 
-40 365   
-50 456  456* 
* Blood volume shifts calculated from percent change in leg volume by conversion factor calculated 
from Musgrave’s paper where both calf and water plethysmograph measurements are given. 
 
 
In addition to integrating the Croston and 
Fitzjerrel model with the Guyton model for 
LBNP/microgravity simulations, NASA modified 
the Guyton model to simulate cephalic fluid shifts 
during HDT experiments ((152)). These 
simulations were specifically intended for 
theoretical countermeasures development, to aid 
in experimental study design to identify any 
undesirable physiologic responses to the 
countermeasures. Simuanonok et al. (1994) 
applied the modified model to investigate if the 
major physiologic effects of a fluid shift can be 
beneficially counteracted by reducing the BV 
before fluid shift (i.e. spaceflight preadaptation). 
They postulated that reducing the BV prior to 
spaceflight would decrease the central volume 
expansion and attenuate the circulatory, 
hormonal, and renal responses. Consequently, it 
was expected that spaceflight preadaptation  
would promote smaller loss of body fluid 
volumes during adaptation to weightlessness; 
which the authors cite as having been supported by two previous short-term water immersion 
experiments and simulation studies. 
 
Figure 21: Hypothesis testing simulation results 
acquired with the modified LBNP model 
compared with experiment data acquired on day 
52 of a Skylab mission (from White et al.(150)). 
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 In support of this study, the Guyton model 
was enhanced with an improved approach for 
erythropoiesis so that BV would reach a stable 
equilibrium at a reasonably reduced volume, 
and normal hematocrit after prolonged HDT. A 
reasonable BV reduction was assumed to be 
10-15% from the initial BV. Furthermore, the 
model parameters were adjusted to match the 
decline in red cell mass with experimental data. 
After the appropriate modifications were made, 
the model was validated for change in 
hematocrit to acute BV reduction by simulating 
a hemorrhage of 15% of BV in 18 minutes. 
Qualitative comparison of the simulation 
results with corresponding experimental data 
from two human subjects showed a good match 
(Figure 22).  
Following the above validation test of the model, a six-degree HDT bed rest simulation was 
executed without preadaptation until a new equilibrium of reduced BV and normal hematocrit 
was attained. The total BV change calculated by the model was 11%. This value was then used as 
the volume to reduce BV in order to test the circulation preadaptation hypothesis.  
The circulatory preadaptation hypothesis was tested in a second simulation by first reducing 
the virtual subject’s BV by 11% at the rate of 41.67 ml/min (the same rate used for the validation 
study) in a supine position. Following blood removal, the virtual subject was set to a 30 minutes 
supine rest without tilt; which was also done for the non-preadapted HDT control simulation.  
Following a 30 minute supine rest, a 70-day six-degree HDT simulation was executed. 
The results of the preadapted 70-day HDT simulation suggested that blood reduction prior to 
HDT may be an effective way to dampen the physiologic responses to fluid shifts and to reduce 
body fluid losses during HDT. More specifically, BV, production of extracellular volume and 
total body water after adaptation are higher than without preadaptation for the first 20 to 30 days 
of bed rest. However, after the first 20 to 30 days, all body fluid volumes in the preadapted 
condition decrease to similar levels of the non-preadapted conditions. Additionally, the 
preadapted HDT simulation showed increased plasma rennin activity and angiotensin levels that 
deviated from homeostasis more than was observed for HDT alone. 
Simuanonok et al. (1994) further support the findings of their simulation by providing 
anecdotal reports of astronauts purposely dehydrating themselves before launch to shed some 
excess fluid volume before flight. They reported one case of a physician astronaut who slept in 
head-down tilt for 10 days or more prior to his five spaceflight missions to preadapt his body to 
fluid shifts. The crewmember reported that they never suffered head congestion, headaches, facial 
edema or space sickness. It was also reported that cosmonauts routinely sleep in HDT for about a 
 
Figure 22: Validation of 15% hemorrhage 
simulation against experimental data for two 
subjects (from Simanonok et al Error! Bookmark 
not defined.(152)). 
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week prior to spaceflight for the same reasons. However, the effect of sleeping in HDT on the 
crewmembers’ BV was not studied or reported. 
In this light, Simuanonok et al. (1994) suggest that pre-flight preadaptation of the circulation 
system to weightlessness may be an effective countermeasure for the undesired effects of fluid 
shift. However, they do stress that such methods must be rigorously tested in ground studies to 
ensure that other risks are not introduced in the process. One safe method may be preadaptation 
via HDT, mild diuretics, dietary modifications, and/or ordinary blood donation a week or so prior 
to launch. Using such methods to preadapt the circulation system to fluid shifts may help reduce 
some of the body fluid losses that compromise orthostatic tolerance when astronauts return to a 
gravity environment. However, the simulation results also suggest that using body fluid reduction 
as a way of preadapting the circulation system may only be effective for missions that do not 
exceed one month. Therefore, it may not be useful for mitigating OI after long duration missions 
such as ISS, or exploration missions to Moon or Mars. 
In all the various modeling and simulation activities that NASA has pursued for 
understanding orthostatic stress resulting from spaceflight missions and spaceflight analog 
studies, there has been only one instance where finite element method was used to represent the 
cardiovascular system (153). Unlike lumped parameter models, finite element models allow for 
high spatial resolution analysis of the biomechanical response and flow dynamics of the 
cardiovascular system. In the study conducted by Sud et al. (1993), the finite element model was 
constructed to investigate how LBNP affects the distribution of blood flow in the cardiovascular 
system. The geometrical and physical data of the various arterial and venous segments were 
compiled from well establish literature sources (153).  
When they simulated LBNP of 3999 Pa and 7998 Pa (30 and 60 mmHg respectively), the 
flow rates, conductance and pressure drops did not change in the vessels that supply blood to the 
upper portion of the systemic circulation. However, changes were observed in the vessels of the 
lower portion of the circulation system. When considering the flow rates in the various limbs and 
organs, the flow rates were unaltered in the in the head, upper extremities, kidneys, spleen and 
liver; which was expected to be the case. Following the LBNP analysis, the authors investigated 
the effect of applying varying negative pressures at different segments of the lower body. The 
results suggested the application of negative pressure at various segments of the lower body may 
produce similar changes when the orders of magnitude of negative pressures are near equivalent 
values. 
Many of the results presented by Sud et al. lack validation and there are several limitations to 
their modeling methodology. The authors caution that the boundary conditions considered for the 
model do not take into account compensatory mechanisms which in practice are preset in the 
cardiovascular system and are highly complex with unknown quantitative measures. The analysis 
was conducted without cardiovascular controls such as HR, venous tone and cardiac contractility. 
Conductance of the various anterior cardiac vein networks were also not obtained from physical 
or geometrical data, but were estimated indirectly. Moreover, blood was modeled as a 
homogeneous Newtonian fluid; which is expected to contribute to the error since blood is a non-
homogeneous fluid containing suspended particulate matter. 
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The finite element model presented by Sud et al. seems to be the first, and perhaps the last 
instance, that NASA has attempted a detailed investigation of the fluid flow and fluid distribution 
in the cardiovascular system during orthostatic stress. Given that finite element math models use 
first principles, they can, with acceptable accuracy, be used to calculate properties of physiologic 
parameters for which direct measured values may be lacking. Such parameters include 
compliance, resistance, capacitance, pressure and flow rates. These values can then be used to 
improve or validate time resolved models similar to those presented by Guyton and Croston for 
systems level analysis to investigate the mechanisms of OI and countermeasures development. 
More recently the works of Summers and others, in collaboration with NASA, have 
substantially expanded on the work of Guyton and applied it to spaceflight research (154–158). 
Over the years, several versions of the model have been used for simulating changes in vital signs 
and hemodynamics similar to those observed in astronauts during spaceflight (156).  It has also 
been used to simulate adaptive compensatory changes produced as fluid shifts from dependent 
areas, such as diuresis with loss of plasma volume and resetting of the baroreceptors while 
effective central volumes and cardiac output are maintained. However, most of the validation 
carried out for the different versions of the model and simulations have been qualitative in nature 
largely based on subject matter expert evaluations for clinical significance. Figure 23 shows an 
example of simulation results with one of the earlier versions of the model known as QCP 
(Quantitative Cardiovascular Physiology). 
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Figure 23: Hemodynamic changes simulated by in microgravity (top panel).  The bottom panel depicts the 
longitudinal changes over several days in fluid distribution and vital signs in a human exposed to 
microgravity.  The first panel shows both general and specific fluid compartments.  In the bar graphs section, the 
single line represents the point where the individual was before the exposure while the solid bar shows their 
current status after being in microgravity for that amount of time.  Also represented are the rates of fluid fluxes at 
that point in time. 
 
One particular area the model was used to analyze is the relative contracture of the 
extracellular fluid compartments and change in capacitance of the veins in the lower extremities 
secondary to this volume loss.  The compliance (pressure-volume relationship) of these veins is 
determined by adrenergic tone, surrounding muscle tone, and external compressive forces of the 
interstitial fluids 
Simulated exposure to microgravity shifts the pressure-volume curve secondary to the loss of 
fluid from the interstitium. During spaceflight this compliance change has little impact on 
hemodynamics due to the low pressure requirements necessary to drive venous return.  Upon 
return into Earth’s gravity, the model predicted a sequestering of blood in these now lower-
compliance vessels with a resulting OI occurring when the astronaut stands ( 
 
Figure 24). 
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Compensatory mechanisms counteract the fall in blood pressure in most individuals, and the 
effects are noted to be transient (Figure 25).  While varying the cardiac function and baroreceptor 
sensitivity can potentiate this intolerance, the change in capacitance of the lower extremity veins 
resulting from a loss of external fluid forces in the dehydrated extracellular compartment was the 
initiating mechanism associated with post-flight orthostasis. 
 
 
A 
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Figure 24: Shows the changes in venous compliance of the lower extremity veins during exposure to 
microgravity over several days (A) and then upon return to the earth environment (B).  The curves show the 
relationship between fluid volume and pressure within the veins (compliance).  The dark lines or curves in A 
are the current state after exposure to microgravity and the lighter line represents the initial condition before 
exposure.  With graph B, the dark lines shows the curve change several minutes after reentry while the lighter 
curve shows the state of the compliance before reentry. 
 
 
B 
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Figure 25: Hemodynamic transients and compensations upon reentry into gravity. The first panel demonstrates 
the vital signs of a returning astronaut during a tilt test after reentry.  This individual (male anatomy) is one who 
is able to compensate for the orthostatic stress and recover his blood pressure after standing. 
 
In a more recent analysis conducted by Summers et al.(158), the model suggested that post-
flight orthostasis is accentuated in women due to their inherent lower center of gravity (COG) by 
about 15% and proportionately larger mass in the lower extremities in comparison to men. When 
this simple anatomic assumption is incorporated into the simulation without any other complex 
physiologic or hormonal changes, the orthostasis was more pronounced and overwhelmed all the 
counter-regulatory interactions as demonstrated by recurring falls in blood pressure upon repeated 
attempts to stand erect (Figure 26). 
 
   48 
 
(a) 
 
(b) 
Figure 26: Hemodynamic transients and compensations upon reentry into gravity. (a) The 
orthostatic mean arterial blood pressure (MAP) response in man when assuming upright 
posture upon reentry to earth’s gravity after one month in the space environment. The drop 
in blood pressure is quickly corrected by compensatory physiologic regulatory mechanisms. 
(b) The “woman model” demonstrates a similar orthostatic blood pressure response when 
assuming upright posture after reentry but with a failure of the compensatory physiologic 
responses to correct the hypotension. (from Summers et al. (158) ) 
 
The findings reported by Melchior et al. (1994) (159) partially support the above results 
relating COG as a possible mechanism gender differentiation in the propensity of OI by showing 
through simulation and experimental results that decrease in lower body capacity diminished 
blood pooling to the lower body during LBNP. The validity of the hypothesized mechanisms 
reported by Summers et al. (2010) can be evaluate further by assessing the relationship of COG 
and OI propensity within the male astronaut population, as well as for the female astronaut 
population. Moreover, a more thorough sensitivity study of the roles the different hypothesized 
mechanism (e.g. hormonal changes, COG, baroreflex deconditioning) would help to further 
assess of COG has a substantial impact as it has been suggested by Summers and colleagues. 
Building on the works completed by NASA, Guyton, Croston and others; Heldt et al. (2002) 
(160) also developed a 12-compartment lumped parameter model that has been successfully 
adapted for studying the hemodynamic response of the cardiovascular system to short-term and 
steady-state orthostatic stress. This includes dynamic change in intravascular volume and arterial 
and cardiovascular baroreflex responses such as those typical of microgravity exposure. Specific 
attention was also give to assessing highly credible compliance values in each compartment and 
the use of environmental pressures, independently assessed at each compartment, and has 
produced a capable simulation environment. The model has been well validated for normal 
hemodynamics, as well as for predicting transient response to HUT, and longer-term adaptation 
to LBNP. Some of the validation results are presented in the Figure 27 and Figure 28 below. 
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Figure 27: Validation of the Heldt et al. (2002) 12-compartment model for predicting transient 
response of (a) mean arterial pressure, (b) mean HR, and (c) mean stroke volume to head-up tilt. The solid 
lines represent simulation results and the discrete points with error bars represent experimental data 
measured across a range of tilt angles.(from Heldt et al. (160) ) 
 
Figure 28: Validation of the Heldt et al. (2002) 12-compartment model for predicting transient 
response of (a) mean arterial pressure, (b) mean HR, and (c) mean stroke volume to LBNP. The solid lines 
represent simulation results and the discrete points with error bars are experimental data measured at 20, 40 
and 60 mmHg of LBNP. (from Heldt et al.(160) ) 
 
   50 
Heldt et al. also demonstrated the utility of their model for hypothesis testing by applying it 
to an illustrative case study to predict the factors that contribute to the overall responses of post-
flight HR resulting from OI. In doing so, they simulated the HR recording of a single astronaut at 
120 days prior to flight by tuning the combined HR gain, combining peripheral resistance gain 
and combining venous gain within physiologic limits. Using the simulated HR response curves as 
a baseline, the simulation was rerun using a different BV, combining parasympathetic and 
sympathetic HR gain, combining peripheral resistance gain, and combining venous tone. The end 
result was a simulation of the post-flight HR shown in Figure, which correlates well with the 
actual measured post-flight HR of the crewmember who had increased HR typical of a 
crewmember with OI. Moreover, although BV has the largest impact on the magnitude of the HR 
response, none of the individual parameter were 
sufficiently adjustable to within physiologic limits 
to reproduce the same results. This suggests that 
overall responses of post-flight HR resulting from 
OI are likely attributable to multiple factors such as 
BV, venous tone and peripheral resistance. 
Mitsis et al. (2006) (161) studied the effects of 
orthostatic stress due under LBNP conditions on 
cerebral hemodynamics using a lumped-parameter 
model. Unlike other lumped parameter models, 
however, the modeling scheme used by Mitsis et al. 
employs non-linear memory behavior observed of 
organs and vessels in the circulatory system that 
causes them to behave like nonlinear capacitors. It 
also captures spontaneous fluctuations of the beat-
to-beat MAP, mean cerebral blood flow velocity 
(MCBFV) in the middle cerebral artery, as well as breath-by-breath end-tidal CO2 concentration 
(PETCO2). Data collected during a previous study on 10 subjects (5 male and 5 female) for beat-
to-beat MAP, MCBFV and breath-to-breath PETCO2 measured continuously under resting and 
LBNP tests to presyncope were used to validate the model. The average LBNP withstood by the 
subjects before syncope was -50 mmHg. 
The model was used to study the dynamic effects of MAP and PETCO2 changes, as well as 
their nonlinear interactions on MCBFV variations at frequencies ranging 0.005 to 0.30 Hz. The 
simulations showed that the linear and nonlinear MAP-MCBFV interaction increased 
substantially above -30 mmHg LBNP in the very low frequency ranges (below 0.04 Hz), 
implying impaired dynamic autoregulation. In contrast, the PETCO2-MCBFV interaction was 
reduced during LBNP at all frequencies, thus suggesting attenuated cerebral vasomotor reactivity 
under dynamic conditions. The authors also speculate that the observed changes may be due to 
progressively reduced cerebral vascular reserve to compensate for the increasingly unstable 
systemic circulation during orthostatic stress that may ultimately lead to cerebral hypoperfusion 
and syncope. 
 
Figure 29: Simulation result of the post-flight 
HR (dashed line) showed a good correlation 
with measured post-flight HR (solid line) of 
the crewmember (from Heldt et al.(160)). 
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2. Utility of Computational Modeling for Future Mission Planning 
As demonstrated by the information presented above, models and simulations can be useful 
for hypothesis testing, gaining insight into countermeasures efficacy to mitigate OI and 
improving experimental design. In a similar way, computational models can beneficially augment 
research activities for hypothesis testing to gain insight on how environmental and physiologic 
factors such as partial gravity, radiation, hypoxic environments, biochemical, hormonal and 
regulatory mechanism may play a role in the risk of OI and crew performance impairment during 
extended missions on the Moon and Mars (162).  
3. Limitations and Gaps 
Most of the modeling work that has been done involves the hydrodynamic and biomechanical 
responses of the cardiovascular system. There has been very little work done in simulating 
biochemical, hormonal and regulatory mechanisms that play a role the response of the 
cardiovascular system to orthostatic stress. The modeling works that have included such 
capabilities (e.g. Guyton model) have not been well validated. To incorporate such capabilities in 
future models, it may be appropriate to leverage works from the biotechnology industry where 
substantial strides have been made in modeling biochemical, hormonal and regulatory processes 
for drug discovery and clinical trials.  
Most of the cardiovascular models developed for spaceflight simulations of orthostatic stress 
are for acute conditions such as tilt table and LBNP. To date, only models derived from the 
Guyton model have been able to simulate chronic cases. However, the Guyton model is also 
limited by the fact that it based on a lumped approach that gives no spatial resolution with regards 
to anatomical changes to key organs such as the heart. In addition, it does not simulate 
cardiovascular physiology on a beat-by-beat basis or breath-by-breath basis. Instead it computes 
all physiologic parameters based on time averaged scale. Additionally, simulating chronic 
cardiovascular or circulatory performance using lumped models are limited by the fact that 
minimal empirical data from human studies are available to accurately capture 
compliance/performance changes of the heart and the arteries over a course of a spaceflight 
mission. Without the correct compliances (i.e. pressure -volume behavior) for the system, the 
outputs of the lumped network models are prone to substantial uncertainty. These limitations can 
be overcome by using spatially resolved finite element and finite volume fluid-structural-tissue 
models of the heart and arteries that can predict these structural changes from first principal 
physics and physiology. 
Rigorous verification, validation, uncertainty quantification (VV&UQ), and code 
documentation are greatly lacking in the current state of practice in spaceflight physiology 
research. In order to use computational models with greater confidence and credibility for 
countermeasures development and hypothesis testing, they should be vetted using formal 
quantitative VV&UQ methods, as well as clear documentation practices. This is especially 
important when the models are applied in areas where clinical data are lacking. 
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I. Partial-Earth Gravity 
 
It is not known if lunar gravity will be sufficient to protect crewmembers from the 
detrimental effects seen during exposure to microgravity.  This is a significant research gap.  No 
studies of orthostatic tolerance have been made in a partial gravity environment, thus the only 
available data are from bed rest studies.  While 6º head-down tilt has been used as an analog for 
the deconditioning associated with microgravity, 10º head-up tilt has been proposed as an analog 
of lunar gravity. By using a 10º head-up tilt, the resultant force along the spinal axis of the body 
is 1/6 that normally seen on Earth (Figure 30). 
 
Figure 30. Representation of the bed that is proposed for lunar gravity simulation testing. This bed 
allows for weight bearing on the feet and some exercise while minimizing friction. 
 
Few studies have been published in which head-up tilt bed rest was used as a lunar gravity 
analog (163–167). The duration of these studies ranged from hours (163–165) to up to six days at 
10º (167) or 11º (166) head-up tilt. Two of these studies simulated the trip to the Moon by using 
four days of 6º head-down tilt bed rest before and after the lunar-analog portion of the studies; 
however, plasma volume was not measured while subjects were in the head-up tilt portion of the 
study. Pavy-Le Traon reports an average plasma volume loss of 11%, but the measurement was 
taken after four days of head-down tilt (167). This does not accurately represent the plasma 
volume during a lunar stay, since the initial plasma volume loss during the analog trip to the 
Moon and any changes during the lunar-analog portion remain unknown. In addition, the lack of 
diet monitoring could have affected the results of the plasma volume analysis. 
Louisy found that venous capacity and emptying time increased significantly during a 
simulated microgravity transit to the Moon and returned to control values on the first day of 
simulated lunar gravity (166), indicating that lunar gravity may reverse some of the detrimental 
effects of short-term microgravity. However, not only did venous capacity significantly increase 
on the first day of the simulated return transit, the increase in venous emptying time was larger 
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than during the simulated transit to the Moon (166). These data suggest the two microgravity 
periods might be characterized by different magnitudes and time courses of change in 
cardiovascular parameters. Additionally, the adaptation of venous distensibility to 1/6 G could not 
be determined due to the short duration of the study. 
Additional studies examining the effects of 10° head-up tilt (163–165) focused on the 
differences between various tilt angles in a supine-tilt-stand protocol where subjects were tilted 
for only six hours. The initial change in cardiovascular parameters characterized by the six hours 
of tilt did not establish any trends, indicating a transient period without predictive value for a 
longer-duration study. These protocols consisted of a supine rest period followed by tilt, such that 
the conclusions cannot be applied to tilt changes from 5° head-down to 10° head-up and vice 
versa. While results from previous studies suggest that exposure to lunar gravity may be 
protective of the microgravity transit period, it should be noted that previous studies of lunar 
analogs are not high fidelity models of what a lunar habitation mission will entail. Firstly, the 
longest lunar-analog portion of these studies lasted only six days, while the eventual lunar outpost 
missions will be on the order of months in duration. Secondly, subjects in previous studies did not 
experience ground reaction forces via a footplate at the end of a bed, but rather relied on friction 
to maintain position while in a head-up tilt position. The muscle contractions experienced from 
ground reaction forces contribute to venous return and fluid homeostasis; therefore, their absence 
would increase plasma volume losses. Thirdly, the subjects only exercised in one study (167), and 
for only 40 minutes a day, whereas astronauts will spend a majority of their day performing tasks 
that will exercise multiple physiological systems. Moderate exercise may, or may not, be 
protective of any deconditioning effects of simply lying in a 10º head-up position. Furthermore, 
while one echocardiographic study has been published on the effects of six hours of 10º head-up 
tilt (165), there are no reports in the literature regarding cardiac function during 10º head-up tilt 
lasting more than six hours.  Finally, the existing knowledge base is composed solely of data from 
male subjects. There is ample evidence that women are more severely affected by the 
deconditioning effects of microgravity (4,6), and therefore, must be included in any partial 
gravity deconditioning study. 
Mars exploration mission scenarios present a number of challenges for the cardiovascular 
system.  Several transit/stay scenarios have been proposed.  Crewmembers will face, at a 
minimum, a 180 day transit to Mars, a significant stay on the Martian surface of 545 days and a 
return transit of 180 days.  A second possible scenario involves much longer transit times and a 
much shorter Martian stay (131 day transit/40day Martian stay/308 day return transit).   
It is extremely difficult to assess the risks of either scenario given the limited data that are 
available.  That being said, Mir and International Space Station (ISS) data suggest that the 
majority of crewmembers (80%) exhibit orthostatic hypotension upon landing after 180 days of 
flight; however, these crewmembers recover quickly.  It is not known to what extent 3/8 G will 
induce orthostatic intolerance.  It is important to note that the impact of this level of orthostatic 
intolerance is likely to be more serious than on Earth due to the lack of medical and support 
staff/infrastructure on Mars.  There are no data that suggest whether a stay on the Martian surface 
will protect or, more accurately, contribute to recovery of crewmembers.  Some believe that 3/8 G 
will be closer to 1 G than microgravity, but there simply is no evidence for this.  The shape of the 
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cardiovascular deconditioning curve between microgravity and 1 G is completely unknown and 
any discussion is, at this point, purely academic.  
The return to Earth gravity will likely be the greatest challenge, from the cardiovascular 
standpoint, ever faced during the manned space program.  Crewmembers are likely to exhibit an 
extremely high rate of orthostatic intolerance with adrenergic dysfunction and significant cardiac 
atrophy.   
An isolation experiment called Mars 500 (520 day duration) was completed in November, 
2011.  The mission was designed to simulate the transit to and from Mars, as well as some 
habitation on the Martian surface.  Some cardiovascular measurements were conducted including 
ECG, BP, and blood markers.  The results from this study have not been published yet, but may 
help determine the baseline cardiovascular effects we may see during a Mars mission that are due 
solely to the isolation of deep space travel. 
This gap is most in need of ground-based research to evaluate various analogs for 3/8 G and 
simulate various mission scenarios before any predictions can be made.  The Integrated 
Cardiovascular Study planned for ISS will be critical for identifying the risks for cardiac structure 
and function.  Computer modeling will play a pivotal role in guiding future research.  Perhaps the 
most useful information will be gathered on long duration lunar missions.     
 
V. Countermeasures 
 
A number of countermeasures to post-spaceflight orthostatic intolerance have been tested 
with varying degrees of success.   
 
A. Fluid Load 
 
All astronauts returning from space are required to ingest a “fluid load” of broth or salt tablets 
and water.  The efficacy of this countermeasure following Shuttle flights was evaluated by Bungo 
et al. (43).  These investigators measured heart rate and blood pressure during a passive stand test 
before and after spaceflight (54 to 194 hours).  Both variables, as well as a cardiovascular index 
of deconditioning, were significantly improved, but not totally restored, when astronauts used the 
fluid loading countermeasure compared to control flights where fluid loading was not used 
(Figure 31). Unfortunately, plasma volume was not measured during this study, so it is not known 
what the direct effect of the countermeasure is on plasma volume.  Several studies have shown 
that there is still a significant plasma volume loss, even with the fluid load, which is now a 
medical requirement.   
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Figure 31.  Effect of reentry Fluid loading on heart rate (43).   
 
The fluid loading protocol currently used by cosmonauts and astronauts returning from ISS 
differs significantly from the protocol previously used by Shuttle astronauts.  Both cosmonauts 
and astronauts increase salt intake with meals over the last several days of the mission. Between 
18 and 20 ml/kg body weight of sodium chloride-water solution or dry salt (0.18-0.20 g/kg body 
weight) with water (18 -20 ml/kg body weight) are consumed 3-4 times in the last 12-20 hours 
before landing (168).  Russian cosmonauts also attempt to increase fluid levels by consuming 
fluids during Chibis sessions at the end of the mission The water-salt additive normally taken 
with food before Chibis LBNP sessions consists of 0.9 g of sodium chloride and 300 ml of water 
(169).  Kozlovskaya et al.(169) report that cosmonauts who participate in the this form of end-of-
mission fluid loading better tolerate the workloads associated with the final phase of the space 
flight mission and the post-flight reconditioning program.  We are unaware of any studies which 
specifically demonstrate the efficacy of the fluid loading countermeasure.  Recent post-flight 
plasma volume data collected as part of NASA’s Functional Task Test Study are confounded by 
the timing of the measurement (~1 day after landing) and by the common practice of intravenous 
administration of fluids soon after landing. 
 
B. Artificial Gravity 
 
Artificial gravity (AG) via short radius centrifugation (SRC) has been suggested as a multi-
system countermeasure to spaceflight deconditioning.  While the idea of artificial gravity to 
prevent orthostatic intolerance is not new(170), the ideal combination of AG magnitude, 
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frequency and duration needed to prevent cardiovascular deconditioning is yet to be determined.  
In a head-down bed rest study, two hours a day of passive standing was sufficient to prevent post-
bed rest hypotension, although four hours a day of passive standing was required to prevent 
plasma volume losses (171).  Hastreiter and Young determined that 1.5 Gz (at the feet)  on a short 
radius centrifuge was required to evoke calf blood flows that were  similar to those when the 
subject was standing (172).  In a non-human primate model, Korolkov et al. showed that SRC AG 
was successful in preventing extracellular fluid loss and orthostatic hypotension resulting from 
bed rest.  Furthermore, they determined that 1.2 Gz, three times a week was more effective than 
higher Gz levels, administered four to five times a week (173).  Iwasaki et al. determined that 
daily 1 hour exposures to 2 Gz (at the heart) was sufficient to prevent the adverse effects of 6° 
head-down tilt bed rest on baroreflex function and plasma volume (174,175).  Finally, combining 
exercise with centrifugation at 0.8, 1.2 and 1.6 Gz (at the feet) was previously shown to be 
effective in maintaining orthostatic tolerance after return from 3 to 28 days of simulated 
microgravity (176).   
The utility of artificial gravity as a whole body countermeasure has gained momentum in the 
last several years.  Three weeks of daily short radius centrifugation (1 Gz at the heart, 2.5 Gz at 
the feet) via the NASA Ames Research Center’s Human Performance Centrifuge was recently 
shown to improve orthostatic tolerance in both ambulatory men and women (177,178).  These 
Ames studies utilized Gz stress in an oscillatory fashion – 2 minutes with 1 Gz at the feet 
followed by 2 minutes with 2.5 Gz at the feet, repeated for up to 45 minutes a day.  At NASA 
Johnson Space Center, a similar study was conducted using a constant 2.5 Gz at the feet for up to 
an hour on 6° head-down tilt bed rested subjects.  This two week study evaluated the 
effectiveness of artificial gravity in 8 treatment subjects compared to 7 control subjects, and 
showed the utility of artificial gravity in preventing bed rest-induced orthostatic intolerance and 
decrements in aerobic capacity (179).  However, this study only enrolled men as women were 
unable to tolerate an hour of centrifugation at the intended study magnitudes (180).  Additional 
centrifuge studies have recently been completed in China (181) and Europe (182) examining 
cardiovascular parameters, yet these experiments did not address orthostatic intolerance. 
Before artificial gravity can be implemented as a viable countermeasure to orthostatic 
intolerance, the dose-response curve needs to be fully understood.  The most efficient duration, 
magnitude and type of artificial gravity has yet to be elucidated.  The NASA Human Research 
Program convened an international working group in February 2014 to begin discussing the 
potential role of artificial gravity in future space exploration. 
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C. Lower Body Negative Pressure 
 
 
Figure 32.  Heart rate response in bed  rest subjects (n=10) before and after a 4 hour “soak” of 
LBNP. From (183) 
 
Lower body negative pressure (LBNP) is another means of producing a head-to-foot Gz force 
to provide an orthostatic challenge (184–186).  By encasing the lower body in a rigid container, 
venous return can be modulated by varying the level of vacuum.  This can be used to simulate 
standing on Earth or other gravity environments, depending on the magnitude of the LBNP.  
Application of LBNP as a countermeasure during spaceflight and bed rest (Figure 32) has been 
used with varying degrees of success in preventing orthostatic intolerance (184–189).  LBNP 
applied after exercise during LBNP has been shown to be effective in attenuating post-bed rest 
orthostatic intolerance (190). The duration and frequency of LBNP required to make it an 
efficient countermeasure, however, is not operationally feasible.   
Lower Body Negative Pressure and Exercise 
In a series of bed rest investigations of increasing durations, a team of investigators led by 
Drs. Alan Hargens and Suzanne Schneider sought to determine whether the combination of lower 
body negative pressure and exercise (LBNPex) would be an effective countermeasure to bed rest-
induced deconditioning, including  orthostatic intolerance, and by extension an appropriate 
countermeasure system for space flight (191).  The investigator team hypothesized that this 
countermeasure could allow astronauts to perform treadmill exercise with axial and ground 
reaction forces (for protection of bone and muscle) similar to or greater than that experienced 
during walking and running in normal gravity while simulating the hydrostatic pressure gradients 
normally experienced by the cardiovascular system.  Although most exercise performed during 
bed rest in the supine position fails to prevent orthostatic intolerance (192), LBNPex might 
preserve plasma volume (193) and stimulate the cardiovascular reflexes used to promote venous 
return and maintain cerebral circulation. 
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In the initial study, 24 male subjects completed 5 d of 6° head-down tilt bed rest, with 
subjects divided into three groups.  Control subjects performed no exercise during bed rest while 
the remaining subjects performed daily intense bouts of either exercise upright on a standard 
treadmill or supine treadmill exercise within the LBNPex device (194).  The exercise protocol 
used by both countermeasure groups consisted of 30 min of interval-style exercise, with 
prescribed intensities up to 90% of pre-bed rest peak oxygen consumption.  The exercise protocol 
previously had been shown to maintain peak oxygen consumption (195) and plasma volume 
(193) during 30 d of bed rest when subjects exercised twice per day on a supine ergometer 
without LBNP.  At the completion of the exercise protocol during this 5-d bed rest, subjects 
remained upright or with their legs positioned against the treadmill belt while LBNP was applied 
(190).  Before and immediately after 5 d of bed rest all subjects participated in head-up tilt test for 
30 min or until presyncope.  After bed rest, tilt tolerance time decreased by ~18% in the control 
group while tolerance time tended to increase in the LBNPex group (~9%) (190,196). 
Orthostatic intolerance, as assessed by cumulative stress index calculated from total time and 
negative pressures achieved during a LBNP ramp protocol, was not maintained in a subsequent 
15-d bed rest study (189).  Seven men performed two 15-d bed rest exposures in a cross-over 
design, in which they participated in a random order once as a control and once as an exercise 
countermeasures subject.  Unfortunately, the countermeasure protocol was ineffective in this 
group of subjects, even though it had been performed each day of bed rest as it had been in the 
previous study.  Although the sub-tolerance cardiovascular responses to LBNP were maintained 
in the countermeasure group and not in the control group, orthostatic tolerance was decreased in 
both groups (countermeasure: -41%, control: -36%).  Two potentially important differences in the 
countermeasure protocol existed which may have influenced these results.   First, the intensity of 
the exercise was reduced, but the duration lengthened, to accommodate the limitations on 
prescribed exercise intensities that was applied by NASA at the time for astronauts.  The peak 
prescribed exercise intensity during this bed rest was 80% of pre-bed rest VO2pk, and the 
protocol was extended from 30 to 40 min.  Second, the subjects in this bed rest study were not 
exposed to the 5-min of post-bed rest LBNP as in the previous 5-d bed rest study.  This additional 
orthostatic challenge, when the subjects were vasodilated from the previous exercise and thermal 
stress, may have been a key component to the success of the countermeasure in the prior study 
(190). 
Subsequent 30-d bed rest studies in male and female twins (16 men, 14 women) confirmed 
the potential efficacy of this countermeasure against space flight-induced orthostatic intolerance 
(190).  In this unique study design, one twin was randomly assigned to the control group and one 
was assigned to the countermeasure group.  Control subjects performed no countermeasures 
throughout the duration of bed rest, while the countermeasure subjects performed the same 
exercise prescription as in the previous 15-d bed rest (189) but with the 5 min of post-exercise 
LBNP used in the 5-d bed rest (196).  Tolerance to a combined tilt and LBNP ramp test was not 
fully protected in the countermeasure group, but the 13% decrease was almost 1/3 of the decrease 
in orthostatic tolerance seen in control subjects (-34%).  Similar to previous observations in this 
series of studies, the cardiovascular response to the sub-tolerance tilt and LBNP was maintained 
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from pre- to post-bed rest in the countermeasure group but was exaggerated in the control group.  
These positive results following a longer duration bed rest study suggest that the repeated bouts 
of the post-exercise orthostatic challenge is an important aspect of the countermeasure 
effectiveness (197), 
Most recently, the combination of the LBNP and exercise countermeasure was tested in 
women during 60 days of bed rest (198).  This bed rest study was different from previous ones in 
this series of investigations in several important ways.  First, the number of LBNP and exercise 
sessions was reduced from 6 d/wk to only 3 d/wk.  A resistive exercise protocol previously shown 
to maintain muscle strength and mass also was performed 3 d/wk, alternating days with the 
aerobic exercise sessions so that the two countermeasures were never performed on the same day.  
Second, although the exercise portion of the LBNP and exercise protocol was maintained from 
previous studies (199,200), the duration of the post-exercise LBNP was extended to 10 minutes.  
It was assumed that a greater orthostatic challenge might be necessary to protect against bed rest-
induced orthostatic challenge after this longer duration bed rest (198), particularly in women who 
are be more susceptible to space flight-induced orthostatic intolerance (6).  Despite this 
modification to the post-exercise LBNP protocol, the countermeasures performed during bed rest 
only partially protected against orthostatic intolerance.  Tolerance, measured by time to 
presyncope during a combined tilt and LBNP protocol, was reduced by 35% in the 
countermeasure subjects but by 50% in this control subjects.  Similar to previous studies from this 
series, sub-tolerance cardiovascular responses to the orthostatic challenge were less in the 
countermeasure group than in the control group (198).  It was likely that the partial protection 
against bed-rest induced orthostatic intolerance resulted primarily from the LBNP and exercise 
protocol since the resistive exercise protocol alone is not effective after 90 d of bed rest (201), but 
the contributions of the respective countermeasures was not specifically elucidated in this study. 
In conclusion, the results from this series of studies suggest that LBNP during and after 
exercise is a potential countermeasure for protection against post-bed rest, and by extension, post-
space flight orthostatic tolerance.  Mechanisms for the protection against post-bed rest orthostatic 
tolerance after bed rest might include from protection of plasma volume (194,199,202) and left 
ventricular mass and function (10,40).  The exclusion of the post-exercise LBNP in the one study 
in which post-bed rest orthostatic tolerance and sub-tolerance cardiovascular responses were not 
maintained suggests the importance of the post-exercise orthostatic challenge.  Further refinement 
of the exercise and post-exercise protocols may elucidate the respective roles of the different 
portions of the countermeasure and result in a more efficacious countermeasure for longer 
duration bed rest and space flight missions.  It should  be noted that in these studies it was 
occasionally necessary to interrupt post-exercise LBNP exposure due to the occurrence of 
presyncopal symptoms.  This occurred more frequently at the start of bed rest and more 
frequently in women (190,198).  The investigator team hypothesized that, although they never 
allowed the situation to progress to the level of presyncope and the subjects always were closely 
monitored, should a subject become unconscious when unmonitored, they would be pulled into 
the LBNP chamber to the point that the waist seal would disconnect from the chamber and the 
negative pressure would be released. 
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D. Pharmacotherapy 
1. Fludrocortisone 
Fludrocortisone is a commonly prescribed 
medication for the treatment of dehydration and 
hypotension.  Seven short duration crewmembers 
took fludrocortisone during spaceflight, seven 
hours before landing. Fludrocortisone successfully 
protected plasma volume (Figure 33), but had no 
effect on post-spaceflight orthostatic hypotension 
(203) thus further inflight testing was discontinued.  
 
2. Midodrine   
 
Midodrine is a relatively specific adrenergic 
agonist that activates alpha-1 receptors on smooth 
muscle in veins and arteries, decreasing venous 
capacity (thus preventing venous pooling) and 
increasing total peripheral resistance (204) in some studies, but not others (205).  Midodrine does 
not cross the blood-brain barrier and therefore has no central stimulant effects (206).  It is almost 
completely absorbed after oral administration and enzymatically hydrolyzed to its active 
metabolite, desglymidodrine, which has a bioavailability of 93% (204,206).  The peak therapeutic 
effect occurs between one and two hours, making it particularly attractive for landing day because 
it can be taken after the final decision to land and have its peak effect close to the time of the 
maximum Gz experienced during landing.  The half-life of the active metabolite is approximately 
4 hours (207).  Midodrine has proven to be a safe and effective therapy for orthostatic 
hypotension due to autonomic dysfunction (204,206,207).  When given to healthy subjects, 
midodrine only modestly increases arterial pressure in supine and standing subjects (increases 
less than 10 mmHg) and decreases heart rate (less than 10 bpm) (204,208).   
Midodrine successfully protected subjects from presyncope (209) after two-week head-down 
tilt bed rest.  Platts et al.  published data from a female astronaut who had previously become 
presyncopal following spaceflight (205). On a subsequent flight she took midodrine one hour 
before her tilt test and was able to stand for the duration of the test (Figure 34).  Her systolic 
blood pressure did not decrease during tilt following midodrine as it had in her prior flight 
without midodrine.  We also found that following the flight with midodrine, her cardiac output 
Figure 33.  Effect of in-flight 
administration of fludrocortisones on 
plasma volume and RBC volume.  
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did not decrease as was seen after her earlier flight.  
 
Figure 34. Midodrine successfully protected systolic pressure, cardiac output and vascular 
resistance during tilt testing (n=1).  First flight was the control flight and the second flight was the 
midodrine trial flight.  Open circles are before flight and closed circles are post-flight (~ 2 hours after 
landing) (205). 
 
Interestingly, total peripheral resistance did not increase following midodrine; in fact, midodrine 
prevented the reflex increase in resistance that was seen in response to tilt following her first 
flight.  This implies a venous mechanism (since a pronounced increased in arterial tone would 
increase resistance) for midodrine.  The lack of increased resistance in this subject is different 
from other reports of midodrine.  We have additional preliminary data for five non-presyncopal 
astronauts in which resistance also did not increase following midodrine.  This may reflect 
differences between subjects that are normovolemic and those that are hypovolemic.  Midodrine 
was the first cardiovascular countermeasure to follow the progression from clinical treatment to 
bed rest testing and finally to spaceflight evaluation.  there is a significant drawback to 
midodrine.  A double-blind, ground-based study in healthy test subjects revealed an increased 
akathisia response when promethazine was given with midodrine (106).  This reponse is likely 
due to the fact that both drugs are metabolized by the cytochrome p450 isozyme 2D6 and in some 
individuals saturation of the isozyme may lead to higher plasma levels than are typically seen 
(210).   Additionally, midodrine has the potential to prolong the QT interval.  Since long duration 
spaceflight (as well as several medications onboard the ISS) also prolongs QT, it was felt that the 
benefits of using midodrine did not outweigh the risks, thus the countermeasure studies of 
midodrine were discontinued. 
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3. Octreotide  
 
Octreotide is a synthetic peptide (octomer) that is an analog of the naturally occurring 
hormone, somatostatin.  It is an FDA approved drug and is used for the treatment of acromegaly, 
various cancers and hypotension in patients with autonomic dysfunction (211,212).  Octreotide 
causes a pronounced increase in splanchnic and peripheral resistance and a decrease in splanchnic 
and peripheral blood flow (211).  This effect is thought to be via a direct effect on the vasculature 
and not as a result of a gastrointestinal endocrine release, as it is present even in the absence of 
changes in gastrointestinal hormone levels (211) and at least 3 somatostatin receptor subtypes 
have been localized in human blood vessels (213).  It has also been postulated that octreotide 
increases venous tone since it produces an increase in cardiac output, possibly through an 
increase in venous return (211). This makes it an especially interesting potential countermeasure 
for spaceflight. 
Octreotide has been clinically tested for its ability to prevent post-prandial hypotension and 
orthostatic hypotension in subjects with autonomic failure (211,212,214).  Octreotide was found 
to be superior to dihydroergotamine for constricting the splanchnic vasculature (211), and it did 
not exhibit the variability (induced by differences in feeding status) that dihydroergotamine did.  
Similarly, octreotide was shown to be superior to midodrine in preventing both post-prandial and 
orthostatic hypotension in 16 patients with autonomic neuropathy (212).  Since midodrine is 
currently the preferred pharmacological countermeasure for post-spaceflight orthostatic 
intolerance, it is essential to compare the two before octreotide is proposed for use in flight.  
Octreotide has been evaluated in the prevention of orthostatic hypotension in healthy females (95) 
with very promising results.  Recently, in a double blind, placebo controlled crossover study,  
Jarvis et al showed that octreotide improved orthostatic tolerance to a 45 minute tilt test (215).  
This benefit was seen in both sexes.  The main drawback of this countermeasure is that it must be 
slowly infused or given subcutaneously.  This is necessary because direct bolus injection may 
lead to a reflex bradycardia and syncope, thus defeating the purpose of the countermeasure.   
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E. Compression Garments 
 
Both the American and Russian space programs utilize compression garments during reentry.  
 
Figure 35.  Survival analysis of tilt test standing times before and after American anti-gravity 
suit (left) and the Russian Kentavr suit (right). 
 
Testing of these garments, using a hypovolemia model to mimic landing day plasma volume 
and orthostatic tolerance, has shown that both garments are 100% effective in preventing 
presyncope during a 15 minute tilt test (Figure 35).   
 
Table 4  Comparisons between control subjects and subjects wearing compression garments 
(Kentavr, AGS) in the supine and standing positions(216).   
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Control: Mean ± SEM 
 
 Presyncopal (n=7)  Nonpresyncopal (n=9) 
 Supine Standing Delta P  Supine Standing Delta P 
Systolic Pressure, mmHg 112.3 ± 4.8 80.4 ± 7.0 -31.8 ± 7.3 *†‡  122.7 ± 4.9 118.6 ± 6.0 -4.1 ± 4.4 ‡ 
Diastolic Pressure, mmHg 66.4 ± 1.5 60.6 ± 5.9 -5.8 ± 5.6   69.6 ± 3.2 72.9 ± 4.6 3.3 ± 2.9  
Heart Rate, beats/min 57.6 ± 2.9 87.9 ± 6.2 30.3 ± 4.6   72.2 ± 4.8 115.6 ± 8.0 43.3 ± 5.9 ?§ 
Stroke Volume, mL 64.7 ± 5.7 24.3 ± 2.6 -40.5 ± 5.6 ¶  58.3 ± 5.5 25.4 ± 3.5 -32.9 ± 4.1  
Cardiac Output, L/min 3.8 ± 0.4 2.1 ± 0.2 -1.7 ± 0.3   4.3 ± 0.5 3.0 ± 0.4 -1.3 ± 0.3  
Total Peripheral Resistance, 
mmHg/L/min 
23.6 ± 3.0 32.7 ± 2.0 9.2 ± 2.6   22.5 ± 2.6 34.4 ± 4.1 11.9 ± 2.5  
 
 
Countermeasure: Mean ± SEM 
 
 Kentavr (n=10)  Anti-g Suit (n=9) 
 Supine Standing Delta P  Supine Standing Delta P 
Systolic Pressure, mmHg 110.9 ± 3.8 112.7 ± 4.8 1.8 ± 3.3 †  117.8 ± 4.6 125.6 ± 5.8 7.8 ± 4.2 * 
Diastolic Pressure, mmHg 69.0 ± 2.8 69.9 ± 3.3 0.9 ± 3.0   74.7 ± 3.3 75.6 ± 2.9 0.9 ± 2.1  
Heart Rate, beats/min 61.6 ± 3.0 77.7 ± 3.7 16.1 ± 1.7 §  65.0 ± 2.2 80.2 ± 3.0 15.2 ± 2.6 ? 
Stroke Volume, mL 60.6 ± 4.7 34.6 ± 2.0 -26.0 ± 3.8   55.8 ± 2.9 34.7 ±2.7 -21.1 ± 2.8 ¶ 
Cardiac Output, L/min 3.7 ± 0.2 2.7 ± 0.1 -1.0 ± 0.2   3.7 ± 0.2 2.8 ± 0.2 -0.9 ± 0.1  
Total Peripheral Resistance, 
mmHg/L/min 
22.7 ± 1.4 32.0 ± 1.8 9.2 ± 2.1   24.7 ± 1.6 34.8 ± 2.9 10.0 ± 2.2  
 
One-Way ANOVA with pairwise comparisons by Holm-Sidek method. *P < 0.001, Presyncopal Delta vs. AGS Delta; †P < 0.001, 
Kentavr Delta vs. Presyncopal Delta; ‡P < 0.001, Nonpresyncopal Delta vs. Presyncopal Delta; ?P < 0.001, Nonpresyncopal Delta vs. 
AGS Delta; §P < 0.001, Nonpresyncopal Delta vs. Kentavr Delta; ¶ P = 0.003, Nonpresyncopal Delta vs. AGS Delta. 
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At termination of the tilt test, the mean systolic blood pressure of presyncopal control 
subjects was 31.8 ± 7.3 mmHg lower than baseline conditions (Table 4).  In contrast, the Kentavr 
subjects’ mean systolic blood pressure was 1.8 ± 3.3 mmHg higher than baseline, and the AGS 
subjects’ mean systolic blood pressure was 7.8 ± 4.2 mmHg higher than baseline.  The decrease 
in systolic blood pressure of presyncopal control subjects was statistically significant as compared 
to the other groups (P < 0.001).  However, the difference in systolic blood pressure between 
Kentavr, AGS and non-presyncopal control subjects was not statistically significant.  
The Kentavr and AGS reduced tachycardia experienced by control subjects during the tilt test 
(Table 4).  Presycopal control subjects’ heart rate increased 30.3 ± 4.6 beats/min during the tilt 
test, while non-presyncopal control subjects’ increased 43.3 ± 5.9 beats/min.  In contrast, Kentavr 
subjects’ heart rate increased 16.1 ± 1.7 beats/min, and AGS subjects’ heart rate increased 15.2 ± 
2.6 beats/min.  The heart rate of non-presyncopal control subjects was significantly higher than 
those wearing either type of anti-gravity suit (P < 0.001).  The heart rates of Kentavr and AGS 
subjects were not significantly different. 
 
Figure 36.  Anti-gravity suits.  The US antigravity suit (left) contains bladders which are pressurized 
to produce compression.  The Russian antigravity suit (Kentavr) utilizes a compressive material and 
lacings to produce compression.   
 
The anti-gravity suits (Figure 36) also helped to maintain stroke volume as compared to 
control subjects (Table 4).  Stroke volume decreased by 40.5 ± 5.6 ml in presyncopal control 
subjects and by 32.9 ± 4.1 ml in non-presyncopal control subjects.  Stroke volume only decreased 
by 21.1± 2.8 ml in AGS subjects and by 26 ± 3.8 ml in Kentavr subjects.  The difference in stroke 
volume between AGS and presyncopal subjects was statistically significant (P = 0.003).  In 
addition, the stroke volume of Kentavr and AGS subjects was significantly higher than non-
presyncopal control subjects over the duration of the tilt test (P < 0.001).  There was no 
significant difference in stroke volume between Kentavr and AGS subjects (P = 0.267).  Based on 
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the testing conditions in this study, there were no significant differences between the 
effectiveness of the Kentavr and the AGS in preventing orthostatic intolerance. 
Both suits are mechanical countermeasures that provide compression of capacitance vessels, 
thereby promoting venous return.  However, there are some operational differences between the 
suits.  One advantage of the AGS is that the pressure can easily be adjusted by the crewmember 
in increments of 0.5 psid (25.9 mmHg); the recommended pressure for re-entry is 1.5 psid (77.7 
mmHg).  A disadvantage of the AGS is that it must be connected to a pressure source to maintain 
compression.  Once it is disconnected so that astronauts can egress the vehicle, the suit deflates as 
the subject moves.  Furthermore, there is evidence that an inflated AGS more than doubles the 
metabolic cost of ambulation and may impede an astronauts ability to safely egress a vehicle in 
the event of an emergency (217).  In addition, some crewmembers find the high pressure over the 
lower abdomen uncomfortable.  The Kentavr is a non-inflatable elastic garment (nominal 
compression ~30 mmHg) that maintains protection after egress.  In fact, cosmonauts often 
continue to wear the Kentavr for several days after landing.  However, one disadvantage of the 
Kentavr is that uncovered areas of the body (for example, knees, feet and groin) may swell 
uncomfortably if the garment is worn for an extended period of time.  It also requires extensive 
crew time and effort to don and adjust the Kentavr.   
Neither garment is ideal; thus, recent laboratory research at the Johnson Space Center has 
been focused on developing a compression garment for exploration class missions that improves 
upon the beneficial features of the AGS and Kentavr.  Because the Kentavr (~30 mmHg) was 
effective at only half the compression applied by the AGS (~75 mmHg), the AGS was evaluated 
at “one click”, or only ~26 mmHg (218).  In this study, orthostatic responses were evaluated in 
hypovolemic test subjects during control conditions (no garment), while utilizing the AGS at the 
lowest operational setting (~26 mmHg), and while utilizing commercially available thigh-high 
compression garments that applied an average pressure of 25 mmHg from the ankle to the top of 
the leg.  As early as the Apollo era, gradient compression stockings were evaluated as a potential 
countermeasure to post-space flight orthostatic intolerance (24).  However, they were difficult to 
don due to the extremely limited space in the Apollo capsule and concerns with reductions in leg 
girth brought into question the effectiveness of commercially available, off-the-shelf garments.  
In the Platts, study, neither the one-click AGS nor the thigh-high compression garments were as 
effective as the three-click AGS or Kentavr in preventing signs and symptoms of orthostatic 
intolerance.  In a separate evaluation of these thigh high stockings compared to the AGS, it was 
found that the stockings did not increase the metabolic cost of walking compared to normal 
athletic attire, unlike the AGS (219).    
Stenger et al evaluated a variation of thigh-high garments that were custom fitted to 5 Space 
Shuttle crew members (220).  Leg circumference was measured by a trained medical professional 
every 1.5 inches from the feet to the top of the leg to allow for individually customized fit.  These 
garments provided 55 mmHg of compression at the ankle, decreasing linearly to 18 mmHg at the 
knee and to 6 mmHg at the top of the leg.  They provided some protection to orthostatic 
intolerance after a short duration Space Shuttle mission, but the lack of abdominal compression 
may have limited their efficacy (221).  Despite evidence that leg-only compression can ameliorate 
vasovagal syncope (222), it is generally accepted that leg-only compression is insufficient (223) 
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and that abdominal compression alone is superior to leg only compression, although compression 
of both the legs and abdomen may be the ideal configuration (221,224).  Therefore, the JSC 
Cardiovascular Team recently developed a three piece gradient compression garment (GCG) 
consisting of thigh-high stockings with overlapping biker-style shorts that provide 55 mmHg at 
the ankle decreasing to 35 mmHg at the knee, 18 mmHg at the top of the leg, and 16 mmHg over 
the abdomen.  The GCG has zippers over the calf (area of highest compression) and along the 
sides of the biker shorts to aid in donning.  The GCG prevented the tachycardia and drop in stroke 
volume during orthostasis normally seen after space flight, and were comfortable to wear in a 
group of seven astronauts tested after 4 different Space Shuttle missions (225).  This same GCG 
was tested after two weeks of 6° head-down tilt bed rest and completely prevented signs of 
orthostatic intolerance in 15 test subjects exposed to 15 minutes of 80 head-up tilt (226).  While 
utilizing these compression garments, blood pressure, heart rate and stroke volume responses to 
head-up tilt were not different after two weeks of bed rest deconditioning.  Furthermore, wearing 
some form of compression garment for 3 days of post-bed rest recovery did not diminish the rate 
of recovery compared to control subjects.  The final step of GCG evaluation will occur in the 
upcoming Field Test study, in which the garment will be tested after long duration (~6 months) 
ISS missions.   
 
VI. Risk in Context of Exploration Mission Operational Scenarios 
 
The principal risk of orthostatic intolerance is the inability of a crewmember to complete 
mission tasks that require extended periods of standing immediately upon landing.  For lunar 
habitation missions, it has not been established what the long term effects of exposure to 1/6 G 
have been; thus, it is unknown whether orthostatic intolerance increases over time or if the lunar 
environment is protective against orthostatic intolerance.  Even less is known about missions to 
intercept an asteroid.  Much depends on duration of mission, distance from Earth and radiation 
exposure.  Missions to Mars (potentially 30 months long) are the least well understood.  While a 
few cosmonauts have lived in low earth orbit for ~ one year, we have no experience with 
missions which involve the extreme exposure to the spaceflight environment that will occur on 
Mars missions.   
A secondary risk is the inability of crewmembers to effectively emergency egress from the 
vehicle in the event of an off-nominal landing.  This may be particularly true for long duration 
crewmembers.  Flight surgeon landing debriefs with first-time flyers on the Space Shuttle 
documented emergency shuttle egress difficulty.  202 medical debriefs were reviewed across 134 
crew members.  55% crew members could egress with no difficulty while 42% could egress with 
some level of difficulty. 13% crew members could not egress using the overhead hatch.  
However, 3% could not egress the side hatch and were unable to exit completely.  Of 41 
Commanders and Pilots (1 female, 40 males), 50% could egress with no difficulty and 50% could 
egress with difficulty.  11% could not egress via the overhead hatch, but all were able to egress 
using the side hatch.  Of 93 Mission Specialists and Payload Specialists (20 females, 73 males), 
46% could egress with no difficulty and 50% could egress with difficulty. 14% could not egress 
using the overhead hatch.  4% of these crew members were unable to egress via the side hatch 
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and therefore unable to exit.  It is not known what fraction of the perceived difficulties were due 
to orthostatic intolerance or neurovestibular issues as that information was not part of the mission 
debriefs. 
 
Furthermore, post-mission crew health can be impacted by orthostatic intolerance.  Several 
instances of post-spaceflight orthostatic intolerance have been documented, though not published.  
For example, one crewmember twice became presyncopal at a podium during a postflight press 
conference and there have been anecdotal reports of crewmembers becoming presyncopal during 
postflight showers, meals and social events.   
These risks can largely be controlled by strict use of a suite of countermeasures including 
fluid loading, reentry compression garments, post-landing compression garments, immediate 
access to medical care and engineering the vehicle to prevent reentry and landing in upright 
positions.  Even with these countermeasures, there is enough uncertainty with return from a Mars 
mission to complete the validation of compression garments following long duration missions.  
Assuming a positive outcome, we can consider the risk as controlled. 
 
VII. Research Gaps:  
CV 3  Orthostatic intolerance is still a potential hazard. 
This remains an issue for long duration flights.  It is an egress issue and a mission performance 
issue.  It is not known if exposure to 1/6 G and 3/8 G will cause orthostatic intolerance or will 
have mitigating/protective effects on orthostatic intolerance upon return to 1 G.   This gap is 
highly dependent of DRM and mission duration 
CV4  Is 1/6 G exposure protective of 1 G orthostatic tolerance? 
It is unknown if long-term exposure to 1/6 G will protect the human body from the 
deconditioning seen during microgravity.  This gap cannot be addressed until crew members 
actually return to the moon, thus this gap is considered inactive. 
 
VIII. Conclusions 
 
Post-spaceflight orthostatic intolerance is prominent in astronauts after long duration 
spaceflight and, though at a lesser degree, is present after short duration spaceflight.  Its 
convoluted etiology has prevented the implementation of a fully successful countermeasure 
although the combined use of multiple countermeasures such as exercise, fluid loading and 
compression garments appears to be effective. Plasma volume losses, female gender and 
cardiovascular deconditioning increase the risk for orthostatic intolerance, where the main risk is 
thought to be a hypoadrenergic response to the upright posture after spaceflight.  Ground-based 
simulated microgravity studies and computer simulations provide additional information on the 
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time course of cardiovascular deconditioning and causes of orthostatic intolerance.  The main 
concern of post-spaceflight orthostatic intolerance is in the case of a non-nominal landing, where 
egress from the spacecraft would be impeded.  In addition, it is unknown if long-term exposure to 
partial gravity environments, such as the Moon or Mars, is protective against the cardiovascular 
effects of microgravity or if orthostatic intolerance will remain a risk in such missions. 
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